




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 213/42, 239/42, 295/22, 213/74, 417/12, 401/12, 215/12, 333/20, 241/12, A61K 31/44, 31/495		A1	(11) International Publication Number: WO 00/12478 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/GB99/02801 (22) International Filing Date: 25 August 1999 (25.08.99) (30) Priority Data: 98402144.4 31 August 1998 (31.08.98) EP 99401351.4 4 June 1999 (04.06.99) EP (71) Applicants (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). ZENECA-PHARMA SA [FR/FR]; "Le Galien", 1, rue des Chauffours, Boîte Postale 127, F-95022 Cergy Cedex (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): BARLAAM, Bernard, Christophe [FR/US]; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). NEWCOMBE, Nicholas, John [GB/GB]; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). TUCKER, Howard [GB/GB]; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). WATERSON, David [GB/GB]; Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		(74) Agent: PHILLIPS, Neil, Godfrey, Alasdair; Astrazeneca PLC, Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP)



(57) Abstract

Arylpiiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP)

The present invention relates to compounds useful in the inhibition of metalloproteinases and in particular to pharmaceutical compositions comprising these, as well as their use.

The compounds of this invention are inhibitors of one or more metalloproteinase enzymes. Metalloproteinases are a superfamily of proteinases (enzymes) whose numbers in recent years have increased dramatically. Based on structural and functional considerations these enzymes have been classified into families and subfamilies as described in N.M. Hooper (1994) FEBS Letters 354:1-6. Examples of metalloproteinases include the matrix metalloproteinases (MMP) such as the collagenases (MMP1, MMP8, MMP13), the gelatinases (MMP2, MMP9), the stromelysins (MMP3, MMP10, MMP11), matrilysin (MMP7), metalloelastase (MMP12), enamelysin (MMP19), the MT-MMPs (MMP14, MMP15, MMP16, MMP17); the reprolysin or adamalysin or MDC family which includes the secretases and sheddases such as TNF converting enzymes (ADAM10 and TACE); the astacin family which include enzymes such as procollagen processing proteinase (PCP); and other metalloprotenases such as aggrecanase, the endothelin converting enzyme family and the angiotensin converting enzyme family.

Metalloproteinases are believed to be important in a plethora of physiological disease processes that involve tissue remodelling such as embryonic development, bone formation and uterine remodelling during menstruation. This is based on the ability of the metalloproteinases to cleave a broad range of matrix substrates such as collagen, proteoglycan and fibronectin. Metalloproteinases are also believed to be important in the processing, or secretion, of biological important cell mediators, such as tumour necrosis factor (TNF); and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD23 (for a more complete list see N. M. Hooper *et al.*, (1997) Biochem J. 321:265-279).

Metalloproteinases have been associated with many disease conditions. Inhibition of the activity of one or more metalloproteinases may well be of benefit in these disease conditions, for example: various inflammatory and allergic diseases such as, inflammation of the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastrointestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis),

inflammation of the skin (especially psoriasis, eczema, dermatitis); in tumour metastasis or invasion; in disease associated with uncontrolled degradation of the extracellular matrix such as osteoarthritis; in bone resorptive disease (such as osteoporosis and Paget's disease)); in diseases associated with aberrant angiogenesis; the enhanced collagen remodelling associated with diabetes, periodontal disease (such as gingivitis), corneal ulceration, ulceration of the skin, post-operative conditions (such as colonic anastomosis) and dermal wound healing; demyelinating diseases of the central and peripheral nervous systems (such as multiple sclerosis); Alzheimer's disease; and extracellular matrix remodelling observed in cardiovascular diseases such as restenosis and atherosclerosis.

A number of metalloproteinase inhibitors are known; different classes of compounds may have different degrees of potency and selectivity for inhibiting various metalloproteinases. We have discovered a new class of compounds that are inhibitors of metalloproteinases and are of particular interest in inhibiting MMP-13, as well as MMP-9. The compounds of this invention have beneficial potency and/or pharmacokinetic properties.

MMP13, or collagenase 3, was initially cloned from a cDNA library derived from a breast tumour [J. M. P. Freije *et al.* (1994) *Journal of Biological Chemistry* 269(24):16766-16773]. PCR-RNA analysis of RNAs from a wide range of tissues indicated that MMP13 expression was limited to breast carcinomas as it was not found in breast fibroadenomas, normal or resting mammary gland, placenta, liver, ovary, uterus, prostate or parotid gland or in breast cancer cell lines (T47-D, MCF-7 and ZR75-1). Subsequent to this observation MMP13 has been detected in transformed epidermal keratinocytes [N. Johansson *et al.*, (1997) *Cell Growth Differ.* 8(2):243-250], squamous cell carcinomas [N. Johansson *et al.*, (1997) *Am. J. Pathol.* 151(2):499-508] and epidermal tumours [K. Airola *et al.*, (1997) *J. Invest. Dermatol.* 109(2):225-231]. These results are suggestive that MMP13 is secreted by transformed epithelial cells and may be involved in the extracellular matrix degradation and cell-matrix interaction associated with metastasis especially as observed in invasive breast cancer lesions and in malignant epithelia growth in skin carcinogenesis.

Recent published data implies that MMP13 plays a role in the turnover of other connective tissues. For instance, consistent with MMP13's substrate specificity and preference for degrading type II collagen [P. G. Mitchell *et al.*, (1996) *J. Clin. Invest.* 97(3):761-768; V. Knauper *et al.*, (1996) *The Biochemical Journal* 271:1544-1550], MMP13 has been hypothesised to serve a role during primary ossification and skeletal remodelling [M.


Stahle-Backdahl *et al.*, (1997) *Lab. Invest.* 76(5):717-728; N. Johansson *et al.*, (1997) *Dev. Dyn.* 208(3):387-397], in destructive joint diseases such as rheumatoid and osteo-arthritis [D. Wernicke *et al.*, (1996) *J. Rheumatol.* 23:590-595; P. G. Mitchell *et al.*, (1996) *J. Clin. Invest.* 97(3):761-768; O. Lindy *et al.*, (1997) *Arthritis Rheum* 40(8):1391-1399]; and during the aseptic loosening of hip replacements [S. Imai *et al.*, (1998) *J. Bone Joint Surg. Br.* 80(4):701-710]. MMP13 has also been implicated in chronic adult periodontitis as it has been localised to the epithelium of chronically inflamed mucosa human gingival tissue [V. J. Uitto *et al.*, (1998) *Am. J. Pathol* 152(6):1489-1499] and in remodelling of the collagenous matrix in chronic wounds [M. Vaalamo *et al.*, (1997) *J. Invest. Dermatol.* 109(1):96-101].

MMP9 (Gelatinase B; 92kDa TypeIV Collagenase; 92kDa Gelatinase) is a secreted protein which was first purified, then cloned and sequenced, in 1989 (S.M. Wilhelm *et al* (1989) *J. Biol Chem.* 264 (29) : 17213-17221. Pubished erratum in *J. Biol Chem.* (1990) 265 (36) : 22570.). A recent review of MMP9 provides an excellent source for detailed information and references on this protease : T.H. Vu & Z. Werb (1998) (In : *Matrix Metalloproteinases*. 1998. Edited by W.C. Parks & R.P. Mecham. pp115 - 148. Academic Press. ISBN 0-12-545090-7). The following points are drawn from that review by T.H. Vu & Z. Werb (1998).

The expression of MMP9 is restricted normally to a few cell types, including trophoblasts, osteoclasts, neutrophils and macrophages. However, it's expression can be induced in these same cells and in other cell types by several mediators, including exposure of the cells to growth factors or cytokines. These are the same mediators often implicated in initiating an inflammatory response. As with other secreted MMPs, MMP9 is released as an inactive Pro-enzyme which is subsequently cleaved to form the enzymatically active enzyme. The proteases required for this activation *in vivo* are not known. The balance of active MMP9 versus inactive enzyme is further regulated *in vivo* by interaction with TIMP-1 (Tissue Inhibitor of Metalloproteinases -1), a naturally-occurring protein. TIMP-1 binds to the C-terminal region of MMP9, leading to inhibition of the catalytic domain of MMP9. The balance of induced expression of ProMMP9, cleavage of Pro- to active MMP9 and the presence of TIMP-1 combine to determine the amount of catalytically active MMP9 which is present at a local site. Proteolytically active MMP9 attacks substrates which include gelatin, elastin, and native Type IV and Type V collagens; it has no activity against native Type I collagen, proteoglycans or laminins.

There has been a growing body of data implicating roles for MMP9 in various physiological and pathological processes. Physiological roles include the invasion of embryonic trophoblasts through the uterine epithelium in the early stages of embryonic implantation; some role in the growth and development of bones; and migration of inflammatory cells from the vasculature into tissues. Increased MMP9 expression has observed in certain pathological conditions, thereby implicating MMP9 in disease processes such as arthritis, tumour metastasis, Alzheimer's, Multiple Sclerosis, and plaque rupture in atherosclerosis leading to acute coronary conditions such as Myocardial Infarction.

In a first aspect of the invention we provide compounds of the formula I



wherein ring B is a monocyclic or bicyclic alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl ring comprising up to 12 ring atoms and containing one or more heteroatoms independently chosen from N, O, and S; alternatively ring B may be biphenyl; ring B may optionally be linked to ring A by a C1-4 alkyl or a C1-4 alkoxy chain linking the 2-position of ring B with a carbon atom alpha to X2;

each R3 is independently selected from hydrogen, halogen, NO₂, COOR wherein R is hydrogen or C1-6alkyl, CN, CF₃, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO₂-C1-6 alkyl, C1-6-alkoxy and up to C10 aryloxy, n is 1,2 or 3;

P is -(CH₂)_n- wherein n = 0, 1, 2, or P is an alkene or alkyne chain of up to six carbon atoms; where X₂ is C, P may be -Het-, -(CH[R₆])_n-Het-, -Het-(CH[R₆])_n-or -Het-(CH[R₆])_n-Het-, wherein Het is selected from -CO-, -S-, SO-, -SO₂-, -NR₆-, or -O- wherein n is 1 or 2, or P may be selected from -CO-N(R₆)-, -N(R₆)-CO-, -SO₂-N(R₆)- and -N(R₆)-SO₂-, and R₆ is hydrogen, C1-6 alkyl, up to C10 aralkyl or up to C9 heteroalkyl;

Ring A is a 5-7 membered aliphatic ring and may optionally be mono- or di-substituted by optionally substituted C1-6 alkyl or C1-6 alkoxy, each substituent being independently selected from halogen, C1-6 alkyl or an oxo group;

X1 and X2 are independently selected from N and C, where a ring substituent on ring A is an oxo group this is preferably adjacent a ring nitrogen atom;

Y is selected from -SO₂- and -CO-;

Z is -CONHOH, Y is -CO- and Q is selected from -C(R₆)(R₇)-, -C(R₆)(R₇)-CH₂-, -N(R₆)-, and -N(R₆)-CH₂- wherein R₆ is as defined above, and solely in relation to Q as here defined, R₆ may also represent up to C₁₀ aryl and up to C₉ heteroaryl, and R₇ is H, C₁-6 alkyl, or together with R₆ forms a carbocyclic or heterocyclic spiro 5, 6 or 7 membered ring, the latter containing at least one heteroatom selected from N, O, and S;

Z is -CONHOH, Y is -SO₂- and Q is selected from -C(R₆)(R₇)-, and —C(R₆)(R₇)-CH₂-;

or Z is -N(OH)CHO and Q is selected from -CH(R₆)-, -CH(R₆)-CH₂-, and -N(R₆)-CH₂-;

R₁ is H, C₁-6 alkyl, C₅-7 cycloalkyl, up to C₁₀aryl, up to C₁₀heteroaryl, up to C₁₂aralkyl, or up to C₁₂heteroarylalkyl, all optionally substituted by up to three groups independently selected from NO₂, CF₃, halogen, C₁-4alkyl, carboxy(C₁-4)alkyl, up to C₆cycloalkyl, -OR₄, -SR₄, C₁-4alkyl substituted with -OR₄, SR₄ (and its oxidised analogues), NR₄, N-Y-R₄, or C₁-4alkyl-Y-NR₄, with the proviso that where R₁ is -OH, -OR₄, -SR₄, or NR₄, or N-Y-R₄ then Z is not -N(OH)CHO, or R₁ is 2,3,4,5,6-pentafluorophenyl;

R₄ is hydrogen, C₁-6 alkyl, up to C₁₀ aryl or up to C₁₀ heteroaryl or up to C₉ aralkyl, each independently optionally substituted by halogen, NO₂, CN, CF₃, C₁-6 alkyl, -S-C₁-6 alkyl, -SO-C₁-6 alkyl, -SO₂-C₁-6 alkyl or C₁-6 alkoxy;

R₂ is H, C₁-6 alkyl, or together with R₁ forms a carbocyclic or heterocyclic spiro 5, 6 or 7 membered ring, the latter containing at least one heteroatom selected from N, O, and S;

also the group Q can be linked to either R₁ or R₂ to form a 5, 6 or 7 membered alkyl or heteroalkyl ring comprising one or more of O, S and N.

Any alkyl groups outlined above may be straight chain or branched.

Convenient values for the above groups include the following:

ring A = a 5-6 membered aliphatic ring, such as a piperazine ring, and may optionally be mono- or di-substituted by optionally substituted C₁-6 alkyl or C₁-6 alkoxy, each substituent being independently selected from halogen, C₁-6 alkyl or an oxo group;

R₃ = hydrogen, halogen, NO₂, CF₃, C₁-4 alkyl, and C₁-4 alkoxy, n is 1 or 2, such as individually 4-fluoro, CF₃, 4-chloro and 3,4-dichloro;

ring B = monocyclic or bicyclic aryl, aralkyl or heteroaryl having up to 10 ring atoms, especially monocyclic aryl, aralkyl or heteroaryl having up to 7 ring atoms, more especially monocyclic aryl or heteroaryl having up to 6 ring atoms, such as a phenyl or pyridyl ring;

P = $-(CH_2)_n-$ wherein n is 0 or 1, or $-O-$, or $-CO-N(R_6)-$;

5 one or both of X2 and X1 = N, or X1 is N, or X2 is C;

Y = $-SO_2-$, Y = $-CO-$;

Q = $-CH(R_6)-$, $-CH(R_6)-CH_2-$, and $-N(R_6)-CH_2-$ wherein R6 is hydrogen or C1-6 alkyl; also where Q is linked to R1 or R2 to form a C5-7 alkyl or heteroalkyl ring such as a cyclohexyl ring;

10 R1 = hydrogen, C1-6alkyl, C5-7 cycloalkyl, up to C12aralkyl, up to

C11heteroarylalkyl, up to C10 aryl or heteroaryl such as up to C6 aryl; all optionally substituted by up to three halogen atoms, or by CF3;

R2 = hydrogen, or together with R1 represent a carbocyclic or heterocyclic spiro 5-or 6 membered ring, such as a tetrahydropyran ring;

15 R4 = up to C10 aryl optionally substituted by halogen, NO2, CN, CF3, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO2-C1-6 alkyl or C1-6 alkoxy;

Z = $-CONHOH-$, Z = $-N(OH)CHO$.

Preferred values for the above groups include the following:

20 R3 = hydrogen, halogen such as chlorine, bromine or fluorine, NO2, CF3, methyl, ethyl, methoxy, ethoxy, particularly methoxy or fluorine;

ring B = a monocyclic aryl, aralkyl or heteroaryl ring having up to 7 ring atoms such as phenyl, biphenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl, especially phenyl, pyridyl and pyrimidyl, more especially phenyl, 2-pyridyl and 2,4-pyrimidyl;

P = a direct bond;

25 both X2 and X1 are N;

Y = $-SO_2-$;

Q = $-CH_2-$;

30 R1 is phenyl, 4-trifluoromethylphenyl, phenethyl, phenpropyl, isobutyl, cyclopentyl, benzyloxymethyl, 3,4-dichlorophenyl, pyridyl, pyridylethyl, thiophenylpropyl, bromothiophenyl, pyrimidinylethyl, pyrimidinylpropyl, pyridylethyl, pyridylpropyl or together with R2 is spirocyclohexane or spiro-4-pyran; R2 is hydrogen


Z = $-N(OH)CHO$.

More preferred values include R3 being halogen, the substituent is preferably meta or para to the ring junction where ring B is an aryl or heteroaryl ring, where ring B is phenyl then especially 4-fluoro and where ring B is pyridyl then 3-, or 4-chloro (as appropriate);


Q = -CH₂-.

- 5 Preferred combinations of Rings B and A include phenyl and piperazinyl; pyridyl and piperazinyl, and pyrimidine and piperazinyl respectively.


Particular alicyclic, fused and heterocyclic rings for ring B include any one of




10



-8-



Particular rings for ring A include any one of



5

and its corresponding seven membered analogue(s).


It will be appreciated that the particular substituents and number of substituents on rings A and B are selected so as to avoid sterically undesirable combinations. This also applies to rings as may be formed by R1 and Q, R2 and Q as well as R6 and R7.

10


Where optically active centres exist in the compounds of formula I, we disclose all individual optically active forms and combinations of these as individual specific embodiments of the invention, as well as their corresponding racemates.

Specific compounds include


-9-




M/Z M+1 (ESP+) 438



M/Z M+1 (ESP+) 455




M/Z M+1 (ESP+) 487




5

M/Z M+1 (ESP+) 454




M/Z M+1 (ESP+) 420


-10-




M/Z M+1 (ESP+) 451



M/Z M+1 (ESP+) 457




M/Z M+1 (ESP+) 438




5

M/Z M+1 (ESP+) 496




M/Z M+1 (ESP+) 471


-11-




M/Z M+1 (ESP+) 528




M/Z M+1 (ESP+) 511



M/Z M+1 (ESP+) 470




M/Z M+1 (ESP+) 495




M/Z M+1 (ESP+) 495


-12-




M/Z M+1 (ESP+) 455




M/Z M+1 (ESP+) 468



M/Z M+1 (ESP+) 455






M/Z M+1 (ESP+) 427





M/Z M+1 (ESP+) 456





-13-




5




-14-



5




-15-



wherein R = phenyl or phenethyl

5 and




wherein R = isobutyl or a spiro-4-pyran ring

As previously outlined the compounds of the invention are metalloproteinase inhibitors, in particular they are inhibitors of MMP13. Each of the above indications for the compounds of the formula I represents an independent and particular embodiment of the invention. Whilst we do not wish to be bound by theoretical considerations, the compounds of the invention are believed to show selective inhibition for any one of the above indications relative to any MMP1 inhibitory activity, by way of non-limiting example they may show 100-1000 fold selectivity over any MMP1 inhibitory activity.

In addition we have found that compounds of the formula I wherein ring B is phenyl, pyridyl (such as 2-pyridyl or 3-pyridyl, especially 2-pyridyl) ring optionally mono- or di-substituted, preferably mono-substituted, by halogen (for example chlorine), P is a direct bond; ring A is a piperazinyl or piperidinyl ring, Y is -SO₂- and Q is C1-4alkylene (for example -CH₂-), especially -CH₂-; R1 is as defined for Formula 1 and is especially 2-phenylpropyl, 2-(2-pyridyl)propyl, 2-(3-pyridyl)propyl, 2-(4-pyridyl)propyl, phenyl, benzyloxymethyl, 4-phenylbutyl, 2-phenylbutyl, or 2-(2-thienyl)propyl; and Z is -N(OH)CHO; are of particular use as aggrecanase inhibitors ie. inhibitors of aggrecan degradation. Of particular note are compounds of the formula I wherein ring B is a phenyl, 3-methylphenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, or 3,4-dichlorophenyl ring or 5-chloro-2-pyridyl; P is a direct bond; ring A is piperidinyl or piperazinyl especially

piperazinyl, Y is SO₂, Q is -CH₂-, Z is -N(OH)CHO and R₁ is phenyl, phenbutylene, phenisopropylene, 2-pyridylethylene, 2-pyridylisopropylene, 3-pyridylisopropylene, 4-pyridylisopropylene, or 4-chlorophenyloxydimethylmethylene. Also of mention are compounds of the formula I wherein ring B is phenyl monosubstituted by chlorine or fluorine, especially 4-chlorophenyl and 4-fluorophenyl; P is a direct bond; ring A is piperidinyl, Y is SO₂, Q is -CH₂-, Z is -CONHOH and R₁ is hydrogen, i-butyl, or spiro-tetrahydropyranyl.

Particular compounds include



B	A	Y	Q	R ₁	Z
4-F-Ph	PIP	SO ₂	CH ₂	CH ₂ CH(CH ₃)Ph	RH
4-F-Ph	PIP	SO ₂	CH ₂	PhCH ₂ CH ₂ CH ₂ CH ₂	RH
3-Cl-Ph	PIP	SO ₂	CH ₂	PhCH ₂ OCH ₂	RH
4-F-Ph	PIP	SO ₂	CH ₂	4-PyridylCH(CH ₃)CH ₂	RH
4-F-Ph	Piperidinyl	SO ₂	CH ₂	PhCH(CH ₃)CH ₂	RH
4-F-Ph	PIP	SO ₂	CH ₂	(R)-2-PhCH(CH ₃)CH ₂	RH
3-Cl-Ph	PIP	SO ₂	CH ₂	3-PyridylCH(CH ₃)CH ₂	RH
3-CH ₃ -Ph	PIP	SO ₂	CH ₂	Ph	RH
4-F-Ph	PIP	SO ₂	CH ₂	CH ₂ CH(CH ₂ CH ₃)Ph	RH
5-Cl-2-Pyridyl	PIP	SO ₂	CH ₂	3-PyridylCH(CH ₃)CH ₂	RH
4-F-Ph	PIP	SO ₂	CH ₂	2-thiophenylCH(CH ₃)CH ₂	RH
4-F-Ph	PIP	SO ₂	CH ₂	2-CH ₃ PhCH ₂ CH ₂	RH
4-F-Ph	Piperidinyl	SO ₂	CH ₂	3-PyridylCH(CH ₃)CH ₂	RH
4-Br-Ph	PIP	SO ₂	CH ₂	PhCH(CH ₃)CH ₂	RH
4-F-Ph	PIP	SO ₂	CH ₂	4-F-PhCH(CH ₃)CH ₂	RH
4-F-Ph	PIP	SO ₂	CH ₂	2-PyrazinylCH(CH ₃)CH ₂	RH

wherein PIP = piperazinyl

RH = reverse hydroxamate group

and R₂ = hydrogen

The compounds of the invention may be provided as pharmaceutically acceptable salts. These include acid addition salts such as hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine.

They may also be provided as in vivo hydrolysable esters. These are pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, for example intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vivo hydrolysable esters for carboxy include methoxymethyl and for hydroxy include formyl and acetyl, especially acetyl.

In order to use a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester and pharmaceutically acceptable carrier.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to hereinabove.

The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.5 to 75 mg/kg body weight (and preferably of 0.5 to 30 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.



Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.

Therefore in a further aspect, the present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use in a method of therapeutic treatment of the human or animal body.

In yet a further aspect the present invention provides a method of treating a metalloproteinase mediated disease condition which comprises administering to a warm-blooded animal a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

In another aspect the present invention provides a process for preparing a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises

a) reacting a compound of the formula (II) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with a compound of the formula (III)






wherein X_1^I represents X or a precursor of X (whether by modification or displacement) or an activated form of X suitable for reaction with Y_1 ;

Y_1 represents Y, a precursor of Y, or an activated form of Y suitable for reaction with X_1^I ; by way of non-limiting example, when X is C then X_1 may be derivatised to include a precursor of Y for reaction with a compound of formula III wherein Y^I is a precursor of Y; Z^I represents a protected form of Z, a precursor of Z (whether by modification or displacement of Z^I) or an activated form of Z;

and where $Q = -(\text{CH}_2)(\text{R}^6)-$ then by reacting a compound of the formula IX with an appropriate compound of the formula $\text{R}^1\text{-CO-R}^2$ to yield an alkene of the formula X, which is then converted to a compound of the formula XI wherein Z^* is a hydroxylamine precursor of the group Z, and then converting Z^* to the group Z, all as set out below:


5



or

b) reacting a compound of the formula (IV)) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with a compound of the formula (V).

10



wherein B^I represents a suitable ring function or substituent group for reaction with P^I , Z^I is as hereinbefore defined; and

P^I represents a suitably activated form of the linker P for reaction with B^I

- 5 or where $X_2 = N$ then P^I may be present on ring A rather than ring B
or, as required, the linker P may be formed by appropriate reaction of precursor groups P'' and P''' provided on rings B^I and A respectively, or vice versa.

A compound of the formula (II) is conveniently prepared by reacting a compound of the formula (VI) with a compound of the formula (VII)



10

- wherein B^I represents a suitable ring function or substituent group, X_2^I represents X or a precursor of X (whether by modification or displacement) or an activated form of X suitable for reaction with B^I and wherein B^I and X_2^I when reacted together provide the linker P
- 15 between ring A and ring B in the compound of formula (II). By way of non-limiting example, when X_2 is N then ring B is suitably derivatised to introduce the linker P via B^I , and when X_2 is C then both ring B and ring A are suitably derivatised to provide the linker P by the reaction of B^I and X_2^I .

It will be appreciated that many of the relevant starting materials are commercially available. In addition the following table shows details of aldehyde intermediates and their corresponding registry numbers in Chemical Abstracts.

RCHO	Chemical Abstracts Registry Numbers
2-methyl-2-(4-chlorophenoxy)propionaldehyde	6390-87-0
2-methyl-2(4-chlorophenylthio)-propionaldehyde	56421-90-0
4-phenoxybutyraldehyde	19790-62-6
cyclohexylacetaldehyde	5664-21-1
3-cyclohexylpropionaldehyde	4361-28-8
4-cyclohexylbutyraldehyde	1860-41-9
3-(3-pyridyl)butyraldehyde	79240-21-4
3-(2-pyridyl)propionaldehyde	2057-32-1
5-phenylvaleraldehyde	36884-28-3
6-phenylhexanal	16387-61-4
3-phenylvaleraldehyde	34097-95-5
3-(2-thienyl)butyraldehyde	63362-02-7
3-(2-methylphenyl)propionaldehyde	19564-40-0
3-phenyl-4-methylvaleraldehyde	54784-84-8
3-(2-pyrazinyl)butyraldehyde	177615-94-0
furan-2-carboxaldehyde	221525-60-6
3-(4-chlorophenyl)propionaldehyde	75677-02-0
3-(4-fluorophenyl)propionaldehyde	63416-70-6
3-(4-pyridyl)propionaldehyde	120690-80-4
4-phenylbutyraldehyde	170650-98-3
2-pyridylcarboxaldehyde	1121-60-4
3-(3-pyridyl)propionaldehyde	1802-16-0
3-(2-furyl)propionaldehyde	4543-51-5
4-(2-pyridyl)butyraldehyde	90943-32-1
4-Bromothiophene-2-carboxaldehyde	18971-75-8
cyclopentanecarboxaldehyde	872-53-7
Benzoxazole, 2-(1-piperazinyl)-(9CI)	111628-39-8
Benzothiazole, 2-(1-piperazinyl)-(9CI)	55745-83-0
Benzoxazole, 5-chloro-2-(1-piperazinyl)-(9CI)	140233-44-9
Benzothiazole, 6-chloro-2-(1-piperazinyl)-(9CI)	153025-29-7
3-pyridyl-5-bromo-carboxaldehyde	113118-81-3

5

Aldehydes without Chemical Abstracts Registry Numbers

3-(2-pyrimidyl) propionaldehyde. To a solution of 2-Bromopyrimidine (7.95 g, 0.05 M) in acetonitrile (150 mL) was added propargylalcohol (4.2 g, 0.075 M), bis-

- 10 (triphenylphosphine)-palladium(II)chloride (750 mg, 1 mM), copper iodide (100 mg, 0.5 mM) and triethylamine (25mL, 0.25 M) and the mixture was stirred and heated at 70°C for 2 hours. An additional amount of propargyl alcohol (2.1 g, 0.038 M), bis-(triphenylphosphine)-

palladium(II)chloride (375 mg, 0.5 mil), and copper iodide (50 mg, 0.25 mil) was then added to the reaction mixture which was stirred and heated at 70°C for an additional hour.

The reaction mixture was evaporated to dryness and the residue which was pre-adsorbed on to silica, chromatographed. Elution with ethyl acetate gave 3-(2-pyrimidyl) prop-2-yn-3-ol as a yellow solid 4.45 g (66 %). NMR (CDCl₃) 2.9 (1H, t), 4.5 (2H, d), 7.3 (1H, d), 8.8 (2H, t), MS found MH⁺ 135

3-(2-pyrimidyl) prop-2-yn-1-ol (4.45 g, 0.033 M) was dissolved in ethyl acetate (140 mL), 10 % Pd/C (890 mg) was added and the mixture stirred under an atmosphere of hydrogen for 6 hours. The reaction mixture was filtered through Celite and the filtrate evaporated to give 3-(2-pyrimidyl) propan-1-ol as a yellow oil, 4.15 g (91 %). NMR (CDCl₃) 2.1 (2H, m), 3.2 (2H, t), 3.8 (2H, t), 7.2 (1H, t), 8.7 (2H, d) MS found MH⁺ 139.

3-(2-pyrimidyl) propan-1-ol was oxidized to give 3-(2-pyrimidyl) propionaldehyde as a yellow oil NMR (CDCl₃) 3.0 (2H, t), 3.4 (2H, t), 7.1 (1H, t), 8.7 (2H, d), 9.9 (1H, s) using the Swern oxidation described in this patent.

Using the procedure described above the following aldehydes were prepared 4-(2-pyrimidyl) butyraldehyde by using 3-butyn-1-ol in place of propargylalcohol NMR CDCl₃ 9.8(1H, s), 8.6 (2H, m), 7.15 (1H, m), 3.0 (2H, m), 2.5 (2H, m), 2.2 (2H, m).

4-(5-pyrimidyl) butyraldehyde by using 3-butyn-1-ol in place of propargylalcohol and 5-bromopyrimidine in place of 2-bromopyrimidine NMR CDCl₃ 9.8 (1H, s), 9.1 (1H, s), 8.6 (2h, s), 2.7 (2H, t), 2.55 (2H, t), 2.0(2H, m).

4-(2-pyridyl) butyraldehyde by using 3-butyn-1-ol in place of propargylalcohol and 2-bromopyridine in place of 2-bromopyrimidine NMR CDCl₃ 9.8 (1H, s); 8.6 (1H, d), 7.6 (1H, m); 7.1(2H m); 2.8 (2H, t); 2.55 (2H, t), 2.0(2H, m).

The compounds of the invention may be evaluated for example in the following assays:

Isolated Enzyme Assays

Matrix Metalloproteinase family including for example MMP13.

Recombinant human proMMP13 may be expressed and purified as described by Knauper *et al.* [V. Knauper *et al.*, (1996) The Biochemical Journal 271:1544-1550 (1996)]. The purified enzyme can be used to monitor inhibitors of activity as follows: purified

proMMP13 is activated using 1mM amino phenyl mercuric acid (APMA), 20 hours at 21°C; the activated MMP13 (11.25ng per assay) is incubated for 4-5 hours at 35°C in assay buffer (0.1M Tris-HCl, pH 7.5 containing 0.1M NaCl, 20mM CaCl₂, 0.02 mM ZnCl and 0.05% (w/v) Brij 35 using the synthetic substrate 7-methoxycoumarin-4-

5 yl)acetyl.Pro.Leu.Gly.Leu.N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl.Ala.Arg.NH₂ in the presence or absence of inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 328nm and λ_{em} 393nm. Percent inhibition is calculated as follows: % Inhibition is equal to the [Fluorescence_{plus inhibitor} - Fluorescence_{background}] divided by the [Fluorescence_{minus inhibitor} - Fluorescence_{background}].

10 A similar protocol can be used for other expressed and purified pro MMPs using substrates and buffers conditions optimal for the particular MMP, for instance as described in C. Graham Knight *et al.*, (1992) FEBS Lett. 296(3):263-266.

Adamalysin family including for example TNF convertase

15 The ability of the compounds to inhibit proTNF α convertase enzyme may be assessed using a partially purified, isolated enzyme assay, the enzyme being obtained from the membranes of THP-1 as described by K. M. Mohler *et al.*, (1994) Nature 370:218-220. The purified enzyme activity and inhibition thereof is determined by incubating the partially purified enzyme in the presence or absence of test compounds using the substrate

20 4',5'-Dimethoxy-fluoresceinyl Ser.Pro.Leu.Ala.Gln.Al.Val.Arg.Ser.Ser.Ser.Arg.Cys(4-(3-succinimid-1-yl)-fluorescein)-NH₂ in assay buffer (50mM Tris HCl, pH 7.4 containing 0.1% (w/v) Triton X-100 and 2mM CaCl₂), at 26°C for 18 hours. The amount of inhibition is determined as for MMP13 except λ_{ex} 490nm and λ_{em} 530nm were used. The substrate was synthesised as follows. The peptidic part of the substrate was assembled on Fmoc-NH-Rink-

25 MBHA-polystyrene resin either manually or on an automated peptide synthesiser by standard methods involving the use of Fmoc-amino acids and O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) as coupling agent with at least a 4- or 5-fold excess of Fmoc-amino acid and HBTU. Ser¹ and Pro² were double-coupled. The following side chain protection strategy was employed; Ser¹(Bu^t), Gln⁵(Trityl), Arg^{8,12}(Pmc or

30 Pbf), Ser^{9,10,11}(Trityl), Cys¹³(Trityl). Following assembly, the N-terminal Fmoc-protecting group was removed by treating the Fmoc-peptidyl-resin with in DMF. The amino-peptidyl-resin so obtained was acylated by treatment for 1.5-2hr at 70°C with 1.5-2 equivalents of

4',5'-dimethoxy-fluorescein-4(5)-carboxylic acid [Khanna & Ullman, (1980) Anal Biochem. 108:156-161) which had been preactivated with diisopropylcarbodiimide and 1-hydroxybenzotriazole in DMF]. The dimethoxyfluoresceinyl-peptide was then simultaneously deprotected and cleaved from the resin by treatment with trifluoroacetic acid containing 5% each of water and triethylsilane. The dimethoxyfluoresceinyl-peptide was isolated by evaporation, trituration with diethyl ether and filtration. The isolated peptide was reacted with 4-(N-maleimido)-fluorescein in DMF containing diisopropylethylamine, the product purified by RP-HPLC and finally isolated by freeze-drying from aqueous acetic acid. The product was characterised by MALDI-TOF MS and amino acid analysis.

Natural Substrates

The activity of the compounds of the invention as inhibitors of aggrecan degradation may be assayed using methods for example based on the disclosures of E. C. Arner *et al.*, (1998) Osteoarthritis and Cartilage 6:214-228; (1999) Journal of Biological Chemistry, 274 (10), 6594-6601 and the antibodies described therein. The potency of compounds to act as inhibitors against collagenases can be determined as described by T. Cawston and A. Barrett (1979) Anal. Biochem. 99:340-345.

Inhibition of metalloproteinase activity in cell/tissue based activity

Test as an agent to inhibit membrane sheddases such as TNF convertase

The ability of the compounds of this invention to inhibit the cellular processing of TNF α production may be assessed in THP-1 cells using an ELISA to detect released TNF essentially as described K. M. Mohler *et al.*, (1994) Nature 370:218-220. In a similar fashion the processing or shedding of other membrane molecules such as those described in N. M. Hooper *et al.*, (1997) Biochem. J. 321:265-279 may be tested using appropriate cell lines and with suitable antibodies to detect the shed-protein.

Test as an agent to inhibit cell based invasion

The ability of the compound of this invention to inhibit the migration of cells in an invasion assay may be determined as described in A. Albini *et al.*, (1987) Cancer Research 47:3239-3245.

Test as an agent to inhibit whole blood TNF sheddase activity

The ability of the compounds of this invention to inhibit TNF α production is assessed in a human whole blood assay where LPS is used to stimulate the release of TNF α . Heparinized (10Units/ml) human blood obtained from volunteers is diluted 1:5 with medium (RPMI1640 + bicarbonate, penicillin, streptomycin and glutamine) and incubated (160 μ l) with 20 μ l of test compound (triplicates), in DMSO or appropriate vehicle, for 30 min at 37°C in a humidified (5%CO₂/95%air) incubator, prior to addition of 20 μ l LPS (E. coli. 0111:B4; final concentration 10 μ g/ml). Each assay includes controls of diluted blood incubated with medium alone (6 wells/plate) or a known TNF α inhibitor as standard. The plates are then incubated for 6 hours at 37°C (humidified incubator), centrifuged (2000rpm for 10 min; 4°C), plasma harvested (50-100 μ l) and stored in 96 well plates at -70°C before subsequent analysis for TNF α concentration by ELISA.

Test as an agent to inhibit in vitro cartilage degradation

The ability of the compounds of this invention to inhibit the degradation of the aggrecan or collagen components of cartilage can be assessed essentially as described by K. M. Bottomley *et al.*, (1997) Biochem J. 323:483-488.

Pharmacodynamic test

To evaluate the clearance properties and bioavailability of the compounds of this invention an ex vivo pharmacodynamic test is employed which utilises the synthetic substrate assays above or alternatively HPLC or Mass spectrometric analysis. This is a generic test which can be used to estimate the clearance rate of compounds across a range of species. Animals (e.g. rats, marmosets) are dosed iv or po with a soluble formulation of compound (such as 20%w/v DMSO, 60% w/v PEG400) and at subsequent time points (e.g. 5, 15, 30, 60, 120, 240, 480, 720, 1220 mins) the blood samples are taken from an appropriate vessel into 10U heparin. Plasma fractions are obtained following centrifugation and the plasma proteins precipitated with acetonitrile (80%w/v final concentration). After 30 mins at -20°C the plasma proteins are sedimented by centrifugation and the supernatant fraction is evaporated to dryness using a Savant speed vac. The sediment is reconstituted in assay buffer and subsequently analysed for compound content using the synthetic substrate assay. Briefly, a compound concentration-response curve is constructed for the compound undergoing

evaluation. Serial dilutions of the reconstituted plasma extracts are assessed for activity and the amount of compound present in the original plasma sample is calculated using the concentration-response curve taking into account the total plasma dilution factor.

5 **In vivo assessment**

Test as an anti-TNF agent

The ability of the compounds of this invention as *ex vivo* TNF α inhibitors is assessed in the rat. Briefly, groups of male Wistar Alderley Park (AP) rats (180-210g) are dosed with compound (6 rats) or drug vehicle (10 rats) by the appropriate route e.g. peroral (p.o.),
10 intraperitoneal (i.p.), subcutaneous (s.c.). Ninety minutes later rats are sacrificed using a rising concentration of CO₂ and bled out via the posterior vena cavae into 5 Units of sodium heparin/ml blood. Blood samples are immediately placed on ice and centrifuged at 2000 rpm for 10 min at 4°C and the harvested plasmas frozen at -20°C for subsequent assay of their effect on TNF α production by LPS-stimulated human blood. The rat plasma samples are
15 thawed and 175 μ l of each sample are added to a set format pattern in a 96U well plate. Fifty μ l of heparinized human blood is then added to each well, mixed and the plate is incubated for 30 min at 37°C (humidified incubator). LPS (25 μ l; final concentration 10 μ g/ml) is added to the wells and incubation continued for a further 5.5 hours. Control wells are incubated with 25 μ l of medium alone. Plates are then centrifuged for 10 min at 2000 rpm and 200 μ l of the
20 supernatants are transferred to a 96 well plate and frozen at -20°C for subsequent analysis of TNF concentration by ELISA.

Data analysis by dedicated software calculates for each compound/dose:

$$\text{Percent inhibition of TNF}\alpha = \frac{\text{Mean TNF}\alpha (\text{Controls}) - \text{Mean TNF}\alpha (\text{Treated})}{\text{Mean TNF}\alpha (\text{Controls})} \times 100$$

25 **Test as an anti-arthritic agent**

Activity of a compound as an anti-arthritic is tested in the collagen-induced arthritis (CIA) as defined by D. E. Trentham *et al.*, (1977) J. Exp. Med. 146, 857. In this model acid soluble native type II collagen causes polyarthritis in rats when administered in Freund's
30 incomplete adjuvant. Similar conditions can be used to induce arthritis in mice and primates.

Test as an anti-cancer agent


Activity of a compound as an anti-cancer agent may be assessed essentially as described in I. J. Fidler (1978) *Methods in Cancer Research* 15:399-439, using for example the B16 cell line (described in B. Hibner *et al.*, Abstract 283 p75 10th NCI-EORTC

5 Symposium, Amsterdam June 16 - 19 1998).

The invention will now be illustrated but not limited by the following Examples:

EXAMPLES**Example 1**

10 **1-[2-(N-formyl-N-hydroxv amino)-2-phenylethanesulfonyl]-4-(4-fluorophenyl)piperazine**



To a solution of 1-[2-(hydroxyamino)-2-phenylethanesulfonyl]-4-(4-fluorophenyl)piperazine (338 mg, 0.89 mmol) in THF (5 ml) and formic acid (2 ml) was added a preformed mixture of formic acid (2 ml) and acetic anhydride (0.5 ml). The mixture was stirred at room temperature for one hour. The mixture was evaporated in vacuo and toluene (2 x 5 ml) was added and evaporated in vacuo. The residue was taken in CH₂Cl₂ - methanol (6 ml, 9 : 1) and silica (1 g) was added. The mixture was stirred for 18 hours. The silica was filtered off and rinsed with CH₂Cl₂ - methanol (9 : 1). The residue was purified on silica gel (eluant: CH₂Cl₂ - MeOH 4 %) to give the title compound as a light orange solid (220 mg, 61 %).

¹H NMR (CDCl₃) : 8.45 and 8.15 (s, 1H), 7.39 (m, 5H), 6.97 (m, 2H), 6.88 (m, 2H), 5.89 and 5.35 (m, 1H), 4.05 and 3.85 (m, 1H), 3.30-3.53 (m, 5H), 3.20-3.10 (m, 4H); MS (ESI): 408 (MH⁺), 430 (MNa⁺); EA: calculated for C₁₉H₂₂FN₃O₄S: C 56.01, H 5.44, N 10.31, S 7.87, Found: C 56.01, H 5.52, N 10.04, S 7.39.

The starting material was prepared as follows :

i) To a solution of 1-(4-fluorophenyl)piperazine (35 g, 194 mmol) and pyridine (17.5 ml) in dry dichloromethane (200 ml) at 0°C was added methanesulfonyl chloride (20 ml , 258 mmol) dropwise. The mixture was stirred for 3 hours at room temperature. The mixture was

washed with water and extracted with dichloromethane (2 x 100 ml). The organic layers were dried with MgSO_4 and evaporated in vacuo. The residue was triturated and washed with methanol to give 1-(4-fluorophenyl)-4-(methanesulfonyl)piperazine (39.35 g) as white crystals. ^1H NMR (CDCl_3): 7.00 (m, 2H), 6.90 (m, 2H), 3.40 (m, 4H), 3.20 (m, 4H), 2.83 (s, 3H).

5

ii) To a solution of LDA [8.5 mmol ; prepared by slow addition of n-butyl lithium (3.5 ml, 8.5 mmol, 2.5 M in hexane) to a solution of diisopropylamine (860 mg, 8.5 mmol) in dry THF (5 ml) at -78°C] at -78°C was added a solution of 1-(4-fluorophenyl)-4-(methanesulfonyl)piperazine (1 g, 3.87 mmol) in THF (25 ml) dropwise. The mixture was stirred at -78°C for 1 hour and a solution of diethylchlorophosphate (670 mg ; 3.87 mmol) in THF (3 ml) was added. The mixture was stirred at -78°C for 1 hour and benzaldehyde (450 mg; 4.24 mmol) in THF (3 ml) was added. The mixture was gently warmed to room temperature and stirred for 18 hours. The mixture was washed with aqueous ammonium chloride and extracted with ethyl acetate. The organic layers were washed with water, brine and dried over MgSO_4 . Purification of the residue on silica (eluant : dichloromethane) afforded 1-(4-fluorophenyl)-4-(trans- β -styrenesulfonyl)piperazine as a white powder (621 mg, 46 %). ^1H NMR (CDCl_3): 7.50 (m, 3H), 7.43 (m, 3H), 6.97 (m, 2H), 6.89 (m, 2H), 6.71 (d, 1H, $J=15.4$ Hz), 3.37 (m, 4H), 3.19 (m, 4H).

10

15

iii) To a solution of 1-(4-fluorophenyl)-4-(trans- β -styrenesulfonyl)piperazine (620 mg, 1.79 mmol) in THF (20 ml) was added hydroxylamine (3 ml, 50 % aqueous solution). The mixture was stirred for 18 hours. The solvent was evaporated. The residue was dissolved in dichloromethane and washed with water. The organic layer was dried on MgSO_4 to give 1-[2-(hydroxyamino)-2-phenylethanesulfonyl]-4-(4-fluorophenyl)piperazine (730 mg). ^1H NMR (CDCl_3): 7.4-7.1 (m, 5H), 6.97 (m, 2H), 6.87 (m, 2H), 5.95 (s br, 1H), 4.74 (s, 1H), 4.60 (dd, 1H, $J=4$ Hz, $J'=8.8$ Hz), 3.56 (dd, 1H, $J=8.8$ Hz, $J'=14.3$ Hz), 3.40 (m, 4H), 3.19 (dd, 1H, $J=4$ Hz, $J'=14.3$ Hz), 3.12 (m, 4H).





20


25

30

Example 2

Similarly the following compounds were obtained:

<u>Compound</u>	<u>Data</u>
	MS (ESI): 436 (MH ⁺), 458 (MNa ⁺)
	MS (ESI): 400 (MH ⁺), 422 (MNa ⁺)
	MS (ESI): 476 (MH ⁺ , ³⁵ Cl) ; 498 (MNa ⁺ , ³⁵ Cl)
	MS (ESI): 422 (MNa ⁺)

5 Example 3**N-hydroxy-3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]propionamide**

To a solution of N-(2,4-dimethoxybenzyloxy)-N-(2,4,6-trimethoxybenzyl)-3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]propionamide (125 mg, 0.19 mmol) in dichloromethane (2 ml) was added triethylsilane (66 μ l, 0.42 mmol) and trifluoroacetic acid (150 μ l). The mixture was stirred at room temperature for 4 hours. The solvents were evaporated in vacuo. The

residue was purified by chromatography on silica (eluant : dichloromethane, then ethyl acetate then dichloromethane -10 % MeOH) to give 35 mg of the title compound.

¹H NMR (DMSO d-6 + CF₃COOD): 7.16 (m, 4H), 3.36 (m, 6H), 3.25 (m, 4H), 2.45 (t, 2H, J = 7.4 Hz); MS (ESI): 332 (MN⁺), 354 (MNa⁺).

5 The starting material was obtained as follows:

i) A solution of 3-mercaptopropionic acid (20 g, 185 mmol) in acetic acid (150 ml) - water (30 ml) at 0° C was reacted with gaseous chlorine (preferably condensed at -78° C, 20 ml). After chlorine had distilled, the solvents were evaporated in vacuo; toluene was added and evaporated to give 1,2-oxathiolane-5-one 2-dioxide (36.12 g).


10 ¹H NMR (DMSO d-6): 2.70 (t, 2H, J= 7.2 Hz), 2.50 (t, 2H, J= 7.2 Hz).

ii) A solution of 1,2-oxathiolane-5-one 2-dioxide (3.8 g, 28 mmol) in thionyl chloride (20 ml) and DMF (5 drops) was stirred at room temperature for 18 hours. The mixture was heated at 40°C for 1 hour. The solvents were evaporated; toluene was added and evaporated in vacuo to give crude 3-chlorosulfonylpropionyl chloride (NMR purity : 70 %, 3.58 g).

15 ¹H NMR (CDCl₃): 4.02 (t, 2H, J= 7.2 Hz), 3.63 (t, 2H, J= 7.2 Hz)


iii) To a solution of 3-chlorosulfonylpropionyl chloride (500 mg, 1.83 mmol, 70 % purity) and diisopropylethylamine (75 µl) in dichloromethane (5 ml) at -78°C was added a solution of O-dimethoxybenzyl-N-trimethoxybenzylhydroxylamine^[Ref1] (664 mg, 1.83 mmol) and diisopropylethylamine (320 µl, 1.83 mmol) in dichloromethane (5 ml) dropwise over 2 hours. After 30 minutes, a solution of 1-(4-fluorophenyl)piperazine (330 mg, 1.83 mmol) and diisopropylethylamine (320 µl, 1.83 mmol) in dichloromethane (5 ml) was added to the reaction mixture. The solution was warmed to room temperature and stirred for 2 hours. The solution was partitioned between dichloromethane and 1N hydrochloric acid. The organic layers were washed with brine and dried over MgSO₄. Chromatography of the residue on silica gel (eluant : ethyl acetate - petroleum ether: gradient from 50/50 to 80/20) gave N-(2,4-dimethoxybenzyloxy)-N-(2,4,6-trimethoxybenzyl)-3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]propionamide (260 mg).

MS (EI): 661 (M⁺)

Example 4**N-hydroxy-3-[4-benzylpiperazine-1-sulfonyl]propionamide**

5 In a manner analogous to that described in Example 3, from 4-benzylpiperazine and 3-chlorosulfonylpropionyl chloride there was obtained the title compound.

¹H NMR (DMSO d-6 + CF₃COOD): 7.50 (m, 5H), 4.41 (s, 2H), 3.78 (m, 2H), 3.41 (m, 4H), 3.18 (m, 2H), 2.43 (t, 2H, J = 7.1 Hz); MS (ESI) : 328 (MH⁺).

10 **Example 5****N-hydroxy-3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]-2-isobutylpropionamide.**

15 To a solution of N-(2,4-dimethoxybenzyloxy)-3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]-2-isobutylpropionamide (220 mg) in dichloromethane (4 ml) was added trifluoroacetic acid (200 μl) and triethylsilane (145 μl). The mixture was stirred at room temperature for 15 minutes, evaporated in vacuo and the residue was purified on silica gel (eluant: dichloromethane-ether-methanol (80:20:0.5) to dichloromethane-methanol (80:20) to
20 give the title compound (88 mg, 56 %).

¹H NMR (DMSO d-6): 10.72 (s, 1H), 7.08 (m, 2H), 6.99 (m, 2H), 3.37 (dd, 1H, J = 8.4 Hz, J' = 14.3 Hz), 3.27 (m, 4H), 3.15 (m, 4H), 3.00 (dd, 1H, J = 4 Hz, J' = 14.3 Hz), 2.62 (m, 1H), 1.6-1.2 (m, 3H), 0.89 (d, 3H, J = 6.6 Hz), 0.85 (d, 3H, J = 6.6 Hz); MS (ESI): 388 (MH⁺), 410 (MNa⁺).

25 The starting material was obtained as follows:

i) A solution of 3-acetylthio-2-isobutylpropionic acid [obtained by Michael addition of thiolacetic acid onto 2-isobutylacrylic acid] (7 g, 34.3 mmol), benzyl bromide (4.29 ml, 36 mmol) and DBU (5.2 ml, 35 mmol) in toluene (55 ml) was stirred for 18 hours at room temperature. The solvents were evaporated in vacuo. The residue was partitioned between ethyl acetate and 5% sodium bicarbonate. The organic layer was washed with brine and dried over MgSO_4 . Purification of the residue by chromatography on silica gel (eluant : dichloromethane-ether (9:1)) gave benzyl 3-acetylthio-2-isobutylpropionate (8.4 g)
MS (ESI) : 317 (MNa^+).

ii) A solution of benzyl 3-acetylthio-2-isobutylpropionate (588 mg, 2 mmol) in acetic acid (12 ml) - water (1.6 ml) at 0°C was reacted with gaseous chloride (preably condensed at -78°C , 1.9 ml). After chlorine had distilled, the solvents are evaporated in vacuo to give crude benzyl 3-chlorosulfonyl-2-isobutylpropionate (630 mg).
MS (EI): 318 (M^+).

iii) A solution of benzyl 3-chlorosulfonyl-2-isobutylpropionate (630 mg, 2 mmol), 1-(4-fluorobenzyl)piperazine (378 mg, 2.1 mmol) and triethylamine (340 μl , 2.4 mmol) in dichloromethane (15 ml) was stirred at 0°C for 18 hours. After evaporation of the solvents, the residue was partitioned between ethyl acetate and water. The organic layer was washed with brine and dried over MgSO_4 . After evaporation of the solvent in vacuo, the residue was purified by chromatography on silica gel (eluant: dichloromethane - ether (9:1) to give benzyl 3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]-2-isobutylpropionate (640 mg)
MS (EI) : 462 (M^+).

iv) A solution of benzyl 3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]-2-isobutylpropionate (630 mg) in methanol (10 ml) was hydrogenated under 40 PSI pressure for 18 hours in the presence of palladium on charcoal (63 mg, 10 %). The catalyst was removed by filtration and the solvents were removed in vacuo to give 3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]-2-isobutylpropionic acid (460 mg).
MS (ESI): 373 (MH^+), 395 (MNa^+).


v) To a solution of 3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]-2-isobutylpropionic acid (230 mg, 0.62 mmol), 2,4-dimethoxybenzylhydroxylamine^[Ref 1] (124 mg, 0.68 mmol), DMAP (75 mg, 0.62 mmol) in DMF (1 ml) was added N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (152 mg, 0.8 mmol). The mixture was stirred at room temperature for 2 days. The reaction mixture was poured in water and extracted with ethyl

acetate. The organic layer was washed with 5% sodium bicarbonate, brine and dried over MgSO_4 . Purification of the residue on silica gel (eluant: dichloromethane - ether: gradient from 9/1 to 8/2) gave N-(2,4-dimethoxybenzyloxy)-3-[4-(4-fluorophenyl)piperazine-1-sulfonyl]-2-isobutylpropionamide (158 mg).

- 5 ^1H NMR (CDCl_3) : 8.21 (s, 1H), 7.30 (m, 1H), 6.97 (m, 2H), 6.88 (m, 2H), 6.46 (m, 2H), 4.95 (m, 2H), 3.82 (s, 6H), 3.50 (dd, 1H, $J = 9$ Hz, $J' = 14.2$ Hz), 3.37 (m, 4H), 3.14 (m, 4H), 2.84 (dd, 1H, $J = 14.2$ Hz, $J' = 2$ Hz), 2.60 (m, 1H), 1.7-1.2 (m, 3H), 0.90 (m, 6H).

Example 6

- 10 4-[4-(4-fluorophenyl)piperazine-1-sulfonylmethyl]tetrahydropyran-4-(N-hydroxy carboxamide)



- 15 To a solution of 4-[4-(4-fluorophenyl)piperazine-1-sulfonylmethyl]tetrahydropyran-4-carboxylic acid (470 mg, 1.21 mmol) in dichloromethane (8 ml) was added oxalyl chloride (700 mg, 5.6 mmol) and DMF (18 μl). The mixture was heated at 35°C for 1 hour. After evaporation of the solvents, the crude acid chloride dissolved in dichloromethane (4 ml) was added to a ice-cooled solution of hydroxylamine (440 μl , 50 % aqueous solution) in THF (8 ml). The mixture was stirred for 90 minutes at room temperature. After evaporation of the solvents, the residue was triturated in dichloromethane-ether-methanol (80 : 20 : 5). The resulting solid was washed with water and ethyl acetate and dried to give the title compound as white crystals (230 mg, 47 %).

- 25 ^1H NMR ($\text{DMSO}-d_6$): 10.56 (s br, 1H), 8.74 (s br, 1H), 7.07 (m, 2H), 6.99 (m, 2H), 3.66 (m, 2H), 3.47 (m, 2H), 3.40 (s, 2H), 3.25 (m, 4H), 3.16 (m, 4H), 1.99 (m, 2H), 1.72 (m, 2H); MS (ESI): 402 (MH^+), 424 (MNa^+).

The starting material was prepared as follows:

- (i) Thiolacetic acid (760 μl , 10 mmol) and tributylphosphine (2.5 ml, 10 mmol) in DMF (5 ml) was added dropwise to a ice-cooled suspension of sodium hydride (530 mg, 60 % in oil, 13 mmol) in DMF (1.5 ml) under an argon atmosphere. The mixture was stirred at 0°C
- 30

for 30 minutes. To the above solution was added 2,7-dioxaspiro[3,5]nonane-1-one^[Ref 2] (1.4 g, 10 mmol) in DMF (10 ml). The mixture was stirred at 0° C for 30 minutes and at room temperature for 18 hours. The reaction mixture was diluted with ether. The precipitate was

5 ¹H NMR (DMSO d-6): 3.65-3.40 (m, 4H), 2.99 (s, 2H), 2.27 (s, 3H), 1.86 (m, 2H), 1.23 (m, 2H).

(ii) Using the same procedure described in Example 5 i), ii), iii), iv), v) except that no DBU was used in step 1, from 4-(acetylthiomethyl)tetrahydropyran-4-carboxylic acid sodium salt was obtained 4-[4-(4-fluorophenyl)piperazine-1-sulfonylmethyl]tetrahydropyran-4-

10 carboxylic acid (490 mg).

4-(acetylthiomethyl)tetrahydropyran-4-(carboxylic acid benzyl ester): MS (ESI): 331 (MNa⁺); 4-(chlorosulfonylmethyl)tetrahydropyran-4-(carboxylic acid benzyl ester): MS (ESI): 354 (MNa⁺); 4-[4-(4-fluorophenyl)piperazine-1-sulfonylmethyl]tetrahydropyran-4-carboxylic acid benzyl ester: MS (ESI): 477 (MH⁺), 499 (MNa⁺); 4-[4-(4-


15 fluorophenyl)piperazine-1-sulfonylmethyl]tetrahydropyran-4-carboxylic acid: MS (ESI): 387 (MH⁺), 409 (MNa⁺).

Ref 1: B.Barlaam, A.Hamon, M.Maudet; Tetrahedron Lett, 1998,39,7865

Ref 2: F. Hoffmann-La Roche, Agouron Pharm.; Eur. Patent Appl. EP 780386.

20 Example 7

1-[2-(N-formyl-N-hydroxyamino)-2-phenylethanesulfonyl]-4-phenylpiperazine



25 To a solution of 1-[2-(hydroxyamino)-2-phenylethanesulfonyl]-phenylpiperazine (140 mg) in THF (0.75 ml) and formic acid (0.25 ml) was added a preformed mixture of formic acid (0.58 ml) and acetic anhydride (0.29 ml). The solution was stirred at ambient

temperature for 18 hours. The mixture was evaporated in vacuo, diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate solution, dried (Na_2SO_4) and evaporated. The residue was purified by chromatography eluting with 1 % methanol in dichloromethane to give 1-phenyl-(4- *trans*-b-styrenesulfonyl)piperazine (420 mg) as a foam (105 mg).

^1H NMR (d_6 -DMSO at 373K): 9.60 (s, 1H), 8.25 (s, 1H), 7.40 (m, 2H), 7.30 (m, 3H), 7.20 (m, 2H), 6.90 (d, 2H), 6.75 (m, 1H), 5.60 (m, 1H), 3.85 (dd, 1H), 3.60 (dd, 1H), 3.30 (m, 4H); 3.15 (m, 4H)
m/z: 390 (M+1).

The starting material was prepared as follows:


A solution of phenylpiperazine (487 mg) in dichloromethane (6 ml) containing triethylamine (0.63 ml) was added dropwise over 5 minutes to *trans*-b-styrenesulfonyl chloride (638 mg) in dichloromethane (4 ml). The solution was stirred at ambient temperature for 18 hours. The solution was diluted with dichloromethane and washed with water, dried (Na_2SO_4) and evaporated. The residue was purified by chromatography eluting with 1 % methanol in dichloromethane to give 1-phenyl-(4- *trans*-b-styrenesulfonyl)piperazine (420 mg) as a solid.

^1H NMR (d_6 -DMSO): 7.75 (m, 2H), 7.40 (m, 4H), 7.30 (d, 1H), 7.20 (dd, 2H), 6.90 (d, 2H), 6.80 (dd, 1H), 3.20 (s, 8H)

m/z 329 (M+1).

To a solution of 1-phenyl-4-(*trans*-b-styrenesulfonyl)piperazine (108 mg) in THF (3 ml) was added hydroxylamine (0.45 ml, 50 % aqueous solution). The mixture was stirred at ambient temperature for 18 hours. Solvent was removed in vacuo and the residue dissolved in dichloromethane, washed with water, dried (Na_2SO_4) and evaporated to give the product 1-[2-(hydroxyamino)-2-phenylethanesulfonyl]-4-phenylpiperazine as a foam (120 mg).

^1H NMR (d_6 -DMSO): 7.50 (m, 1H), 7.40 (m, 2H), 7.30 (m, 5H), 6.90 (d, 2H), 6.80 (dd, 1H), 5.90 (m, 1H), 4.20 (m, 1H), 3.60 (dd, 1H), 3.40 (dd, 1H), 3.20 (m, 4H); 3.10 (m, 4H) m/z 362 (M+1).

Example 8**1-[2-(N-formyl-N-hydroxyamino)-2-(quinoline-4-yl)ethane-1-sulfonyl]-4-(4-fluorophenyl)piperazine**

5

To a suspension of 1-[2-(N-hydroxyamino)-2-(quinoline-4-yl)ethane-1-sulfonyl]-4-(4-fluorophenyl)piperazine (148 mg, 0.34 mmol) in THF (2 ml) - CH₂Cl₂ (2 ml) was added 5-methyl-3-formyl-1,3,4-thiadiazole-2(3H)-thione⁽¹⁾ (140 mg, 0.87 mmol). The mixture was stirred for 3 h. After addition of methanol (2 ml) and silica (1 g), the mixture was stirred for 18 h. The solids were filtered. The filtrates were washed with sat. NaHCO₃ and brine. Evaporation of the solvents followed by trituration in acetonitrile - CH₂Cl₂ gave the starting material (60 mg). Chromatography of the mother liquors with acetonitrile - CH₂Cl₂ (1:1) gave the title compound (20 mg, 13%).


15 ¹H-NMR (CDCl₃): 8.97 (m, 1H), 8.21 (m, 2H), 8.01 (s, 1H), 7.8-7.65 (m, 3H), 6.97 (m, 2H), 6.86 (m, 2H), 5.66 (m, 1H), 3.55-3.1 (m, 10H); MS (ESI): 459 (MH⁺).

The starting material was prepared from quinoline-4-carboxaldehyde and 1-(4-fluorophenyl)-4-(methanesulfonyl)piperazine in a similar manner to Example 1 ii-iii): 188 mg; MS (ESI): 431 (MH⁺); HPLC t_R (Column TSKgel super ODS 2mm 4.6mm x 5cm, gradient methanol/ water 20 to 100% in 5 min, flow rate: 1.4 ml/mn): 3.43 min

20

(1) Yazawa, H.; Goto, S. Tetrahedron Lett., **1985**, 26, 3703

25

Example 9**1-[1-(N-formyl-N-hydroxyamino)-1-(3,4-dichlorophenyl)pentane-2-sulfonyl]-4-(4-fluorophenyl)piperazine.**

5

Similarly to Example 1, the syn and anti diastereoisomers of 1-[1-(N-hydroxyamino)-1-(3,4-dichlorophenyl)pentane-2-sulfonyl]-4-(4-fluorophenyl)piperazine were converted to the title compound (as 2 diastereoisomers):

10 - diastereoisomer 1 from the less polar hydroxylamine: 36 mg, 70%; $^1\text{H-NMR}$ (CDCl_3): 8.45 and 8.10 (s, 1H), 7.6-7.2 (m, 3H), 7.0-6.8 (m, 2H), 5.96 and 5.18 (m, 1H), 3.8-3.4 (m, 5H), 2.9-3.15 (m, 4H), 2.0-1.0 (m, 4H), 0.88 and 0.76 (t, 3H, $J = 7 \text{ Hz}$); MS (ESI): 540 ($\text{M}\{^{35}\text{Cl}, ^{35}\text{Cl}\}\text{Na}^+$), 542 ($\text{M}\{^{37}\text{Cl}, ^{35}\text{Cl}\}\text{Na}^+$).

15 - diastereoisomer 2 from the more polar hydroxylamine: 49 mg, 63%; $^1\text{H-NMR}$ (CDCl_3): 8.28 and 8.13 (s, 1H), 7.6-7.2 (m, 3H), 7.0-6.85 (m, 2H), 5.54 and 5.02 (m, 1H), 3.45-3.9 (m, 5H), 3.15 (m, 4H), 1.7-1.2 (m, 4H), 0.76 (t, 3H, $J = 7 \text{ Hz}$); MS (ESI): 540 ($\text{M}\{^{35}\text{Cl}, ^{35}\text{Cl}\}\text{Na}^+$), 542 ($\text{M}\{^{37}\text{Cl}, ^{35}\text{Cl}\}\text{Na}^+$).

The starting material was prepared as follows:

20 Similarly to Example 1 i), from 1-(4-fluorophenyl)piperazine and 1-butan-1-sulfonyl chloride was obtained 1-(4-fluorophenyl)-4-(butane-1-sulfonyl)piperazine (1.84 g); similarly to Example 1 ii), this was reacted with 3,4-dichlorobenzaldehyde to give 4-(4-fluorophenyl)-1-[1-(3,4-dichlorophenyl)pent-1-ene-2-sulfonyl]piperazine as a mixture of Z/E isomers (330 mg, 22%); MS (ESI): 457 ($\text{M}\{^{35}\text{Cl}, ^{35}\text{Cl}\}\text{H}^+$), 459 ($\text{M}\{^{37}\text{Cl}, ^{35}\text{Cl}\}\text{H}^+$); similarly to Example 1 iii) except that the mixture was refluxed for 3 days, this was converted to 1-[1-(N-hydroxyamino)-1-(3,4-dichlorophenyl)pentane-2-sulfonyl]-4-(4-fluorophenyl)piperazine as the syn and anti diastereoisomers.

25


Less polar isomer (50 mg, 15%) (TLC: eluant EtOAc - CH_2Cl_2 - petroleum ether (15-45-50); $^1\text{H-NMR}$ (CDCl_3): 7.53 (d, 1H, $J = 2.2 \text{ Hz}$), 7.46 (d, 1H, $J = 7.4 \text{ Hz}$), 7.27 (m, 1H),

6.97 (m, 2H), 6.88 (m, 2H), 4.63 (m, 1H), 3.55 (m, 4H), 3.16 (m, 5H), 1.75 (m, 2H), 1.4 (m, 1H), 1.2 (m, 1H), 0.77 (t, 3H, J= 7.4 Hz).

More polar isomer (76 mg, 23 %); ¹H-NMR (CDCl₃) : 7.52 (d, 1H, J= 2 Hz), 7.45 (d, 1H, J= 8 Hz), 7.27 (m, 1H), 6.99 (m, 2H), 6.89 (m, 2H), 4.42 (m, 1H), 3.55 (m, 4H), 3.41 (m, 1H), 3.14 (m, 4H), 1.6 (m, 2H), 1.25 (m, 2H), 0.76 (t, 3H, J= 7.3 Hz).

Example 10

Trans 1-[2-(N-formyl-N-hydroxyamino)cyclohexane-1-sulfonyl]-4-(4-fluorophenyl)-piperazine.



Similarly to Example 1, from trans 1-[2-(N-hydroxyamino)cyclohexane-1-sulfonyl]-4-(4-fluorophenyl)piperazine was obtained the title compound (68 mg, 23%).

¹H-NMR (CDCl₃) : 8.39 and 8.02 (s, 1H), 6.98 (m, 2H), 6.88 (m, 2H), 4.40 and 3.92 (m, 1H), 3.35-3.55 (m, 5H), 3.15 (m, 4H), 2.35 (m, 1H), 2.0-1.8 (m, 3H), 1.2-1.6 (m, 4H); MS (ESI): 408 (MNa⁺).

The starting material was obtained as follows :

i) To a solution of LDA (51 mmol, prepared by slow addition of n-butyl lithium (20.4 ml, 2.5M in hexane, 51 mmol) to a solution of diisopropylamine (5.16 g, 51 mmol) in THF (30 ml) at -78°C) at -78°C was added a solution of 1-(4-fluorophenyl)-4-(methanesulfonyl)-piperazine (6 g, 23.2 mmol) in THF (150 ml). The mixture was stirred for 1 h at -78°C. A solution of 5-chlorovaleryl chloride (4 g, 25.8 mmol) in THF (20 ml) was added dropwise. The mixture was stirred at -78°C for 1 h and at room temperature for 18 h. The solution was diluted with EtOAc and washed with sat. NH₄Cl and brine and dried over MgSO₄. Chromatography of the residue on silica gel (eluant : EtOAc - CH₂Cl₂ - petroleum ether (15:35:50)) afforded 1-(6-chloro-2-hexanone-1-sulfonyl)-4-(4-fluorophenyl)piperazine (5.22 g, 60%) as white crystals: MS (ESI): 399 (MNa⁺).

ii) A mixture of this compound (5.22 g, 13.9 mmol) and NaI (42 g) in acetone (90 ml) was refluxed for 5 h. After cooling and partitioning between EtOAc and water, the organic

layer was washed with 10 % NaHSO₃ and brine, and dried over MgSO₄ to give 1-(6-iodo-2-hexanone-1-sulfonyl)-4-(4-fluorophenyl)piperazine (6.13 g, quantitative) as yellowish crystals: ¹H-NMR (CDCl₃): 6.98 (m, 2H), 6.88 (m, 2H), 4.00 (s, 2H), 3.46 (t, 4H, J= 4.8 Hz), 3.19 (t, 2H, J= 6.6 Hz), 3.16 (t, 4H, J= 4.8 Hz), 2.79 (t, 2H, J= 6.6 Hz), 1.85 (m, 2H), 1.74 (m, 2H).

iii) A mixture of this compound (1.27 g, 4.85 mmol) and cesium carbonate (8 g, 24.5 mmol) in CH₂Cl₂ (90 ml) was stirred at room temperature for 4 h. To the mixture was slowly added water and 2N HCl until pH ~ 7. The mixture was extracted with CH₂Cl₂. The organic layer was dried over MgSO₄. Chromatography on silica gel (eluant: EtOAc - petroleum ether (4:6)) afforded 1-(cyclohexanone-2-sulfonyl)-4-(4-fluorophenyl)piperazine (880 mg, 53%). ¹H-NMR (CDCl₃): 6.97 (m, 2H), 6.88 (m, 2H), 3.83 (m, 1H), 3.48 (m, 4H), 3.12 (m, 4H), 2.81 (m, 1H), 2.54 (m, 1H), 2.46 (m, 1H), 2.2-2.0 (m, 3H), 1.75 (m, 2H); MS (ESI): 363 (MNa⁺); IR: 1716.

Further elution (EtOAc - petroleum ether (6:4)) afforded 1-[(tetrahydropyran-2-yl)methylidenesulfonyl]-4-(4-fluorophenyl)piperazine (630 mg, 38 %): ¹H-NMR (CDCl₃): 6.98 (m, 2H), 6.87 (m, 2H), 5.21 (s, 1H), 4.14 (t, 2H, J= 5.2 Hz), 3.32 (m, 4H), 3.15 (m, 4H), 2.35 (t, 2H, J= 6.6 Hz), 1.82 (m, 4H); MS (ESI): 363 (MNa⁺).

iv) To a solution of 1-(cyclohexanone-2-sulfonyl)-4-(4-fluorophenyl)piperazine (284 mg, 0.83 mmol) in methanol-THF (16 ml, 3:1) at 0°C was added sodium borohydride (3.7 mg, 1 mmol). The mixture was stirred at 0°C for 30 min and at room temperature for 1 h 30. The solvents were evaporated. Saturated NH₄Cl and water were added. The precipitate was filtered, washed with water and dried to give 1-(2-cyclohexanol-1-sulfonyl)-4-(4-fluorophenyl)piperazine (250 mg, 88%): MS (ESI): 343 (MH⁺).


v) To a solution of 1-(2-cyclohexanol-1-sulfonyl)-4-(4-fluorophenyl)piperazine (310 mg, 0.9 mmol) in THF (15 ml) was added triphenylphosphine (1.18 g; 4.5 mmol) and DEAD (712 µl, 4.5 mmol) dropwise. The mixture was stirred at room temperature for 18 h. Evaporation of the solvents and purification on silica gel (eluant: EtOAc -petroleum ether, gradient from 2:8 to 3:7) gave 1-[1-cyclohexene-1-sulfonyl]-4-(4-fluorophenyl)piperazine (285 mg, 98%): MS (ESI): 325 (MH⁺).

vi) Similarly to Example 1 iii) except that the reaction was heated at 65°C for 30 h, from 1-(1-cyclohexene-1-sulfonyl)-4-(4-fluorophenyl)piperazine (280 mg, 0.86 mg) was obtained trans 1-[2-(N-hydroxyamino)cyclohexane-1-sulfonyl]-4-(4-fluorophenyl)piperazine

(270 mg, 88%): $^1\text{H-NMR}$ (CDCl_3): 6.98 (m, 2H), 6.88 (m, 2H), 3.54 (m, 4H), 3.34 (m, 2H), 3.14 (m, 4H), 2.30 (m, 1H), 2.17 (m, 1H), 2.05 (m, 1H), 1.9-1.2 (m, 5H); MS (ESI): 358 (MH^+).

5 Example 11

Cis 1-[2-(N-formyl-N-hydroxyamino)cyclohexane-1-sulfonyl]-4-(4-fluorophenyl)-piperazine.



10

Similarly to Example 1, from cis 1-[2-(N-hydroxyamino)cyclohexane-1-sulfonyl]-4-(4-fluorophenyl)piperazine was obtained the title compound (18 mg, 18%): $^1\text{H-NMR}$ (CDCl_3): 8.39 and 8.07 (s, 1H), 6.98 (m, 2H), 6.88 (m, 2H), 4.77 and 4.25 (m, 1H), 3.48 (m, 15 5H), 3.13 (m, 4H), 2.25-1.3 (m, 8H); MS (ESI) : 408 (MNa^+).


The starting material was obtained as follows :

- i) A mixture of 1-(cyclohexanone-2-sulfonyl)-4-(4-fluorophenyl)piperazine (50 mg, 0.14 mmol), hydroxylamine hydrochloride (51 mg, 0.73 mmol) and potassium acetate (72 mg, 0.73 mmol) in methanol (5 ml) was heated at 70°C for 4 h. The solvents were evaporated.
- 20 After partitioning between EtOAc and water, the organic layer was washed with brine and dried over MgSO_4 to give 1-[2-(N-hydroxyimino)cyclohexane-1-sulfonyl]-4-(4-fluorophenyl)piperazine as a white solid (48 mg, 94%): MS (ESI): 356 (MH^+).
- ii) To this compound (210 mg, 0.6 mmol) in a mixture of THF - acetic acid (7 ml, 1:1) was added sodium cyanoborohydride (276 mg, 4.4 mmol). The mixture was stirred at room
- 25 temperature for 18 h. Water was added and the pH was adjusted to 9. The mixture was extracted with EtOAc. The organic layer was washed with brine and dried over MgSO_4 . Chromatography on silica (eluant: EtOAc - petroleum ether, gradient from 1:1 to 8:2) afforded cis 1-[2-(N-hydroxyamino)cyclohexane-1-sulfonyl]-4-(4-fluorophenyl)piperazine (97

mg, 45%): $^1\text{H-NMR}$ (CDCl_3): 6.98 (m, 2H), 6.89 (m, 2H), 3.63 (m, 1H), 3.52 (m, 4H), 3.24 (dt, 1H, $J_d = 10.6$ Hz, $J_t = 3.5$ Hz), 3.15 (m, 4H), 2.2-1.2 (m, 8H); MS (ESI) : 358 (MH^+).

Example 12

5 The following compounds were made using the method outlined in Example 1:



* = M-H

R2 = hydrogen

10

PIP = piperazinyl

RH = reverse hydroxamate

A = carboxylic acid

Mp Low	Mp High	M+H	B	A	Y	Q	R1	Z
117	117	492-494	4-F-Ph	PIP	SO2	CH2	2-(5-Br-thiophene)	RH
128	128	409	4-F-Ph	PIP	SO2	CH2	3-Pyridyl	RH
125	125	414	4-F-Ph	PIP	SO2	CH2	2-thiophenyl	RH
135	135	414	4-F-Ph	PIP	SO2	CH2	3-thiophenyl	RH
		409	4-F-Ph	PIP	SO2	CH2	2-Pyridyl	RH
		372	4-F-Ph	PIP	CO	N	(S)-PhCH2	A
		426	4-F-Ph	PIP	SO2	CH2	4-F-Ph	RH
		358*	4-F-Ph	PIP	SO2	CH2	Gem-di-Me	RH
		450	4-F-Ph	2-Me-PIP	SO2	CH2	PhCH2CH2	RH
		498*	4-F-Ph	PIP	SO2	CH2	4-Cl-PhOC(Me)2	RH
129	130	389	4-Ph	Piperidinyl	SO2	CH2	Ph	RH
		500-502	3,4-di-Cl-Ph	PIP	SO2	CH2	CH2CH(CH3)Ph	RH
		466	4-F-Ph	PIP	SO2	CH2	PhOCH2CH2CH2	RH
110	110	514*	4-Cl-Ph	PIP	SO2	CH2	4-Cl-PhOC(Me)2	RH
138	140	550-552	3,4-di-Cl-Ph	PIP	SO2	CH2	4-Cl-PhOC(Me)2	RH

Mp Low	Mp High	M+H	B	A	Y	Q	R1	Z
69	70	389	Ph	4-Piperidinyl	SO2	CH2	Ph	RH
		456	4-F-Ph	PIP	SO2	CH2	c-HexylCH2CH2CH2	RH
		442	4-F-Ph	PIP	SO2	CH2	CyclohexylCH2CH2	RH
139	140	407	4-F-Ph	Piperidinyl	SO2	CH2	Ph	RH
172	172	516	4-F-Ph	PIP	SO2	CH2	4-Cl-PhSC(Me)2	RH
		517-519	5-Cl-2-Pyridyl	PIP	SO2	CH2	4-Cl-PhOC(Me)2	RH
		516-518	3-Cl-Ph	PIP	SO2	CH2	4-Cl-PhOC(Me)2	RH
		505	4-F-Ph	PIP	SO2	CH2	N-PhCH2-4-Piperidinyl	RH
104	104	548	4-F-Ph	PIP	SO2	CH2	4-Cl-PhSO2C(Me)2	RH
135	135	451	4-F-Ph	PIP	SO2	CH2	3-PyridylCH(CH3)CH2	RH
100	100	451	4-F-Ph	PIP	SO2	CH2	4-PyridylCH(CH3)CH2	RH
65	65	451	4-F-Ph	PIP	SO2	CH2	2-ylidylCH(CH3)CH2	RH
69	70	449	4-F-Ph	Piperidinyl	SO2	CH2	PhCH(CH3)CH2	RH
54	55	436	4-F-Ph	Piperidinyl	SO2	CH2	2-PyridylCH2CH2	RH
66	67	449-501	4-F-Ph	Piperidinyl	SO2	CH2	4-Cl-PhOC(Me)2	RH
		480	3-Cl-Ph	PIP	SO2	CH2	PhCH2CH2CH2CH2	RH
50	55	480-482	4-Cl-Ph	PIP	SO2	CH2	PhCH2CH2CH2CH2	RH
		450	4-F-Ph	PIP	SO2	CH2	(S)-2-PhCH(CH3)CH2	RH
		450	4-F-Ph	PIP	SO2	CH2	(R)-2-PhCH(CH3)CH2	RH
		467	3-Cl-Ph	PIP	SO2	CH2	3-PyridylCH(CH3)CH2	RH
		464	4-F-Ph	PIP	SO2	CH2	CH2CH(CH2CH3)Ph	RH
160	163	428	4-F-Ph	PIP	SO2	CH2	CH2c-hexyl	RH
		468	5-Cl-2-Pyridyl	PIP	SO2	CH2	3-PyridylCH(CH3)CH2	RH
		456	4-F-Ph	PIP	SO2	CH2	2-thiophenylCH(CH3)CH2	RH
45	46	478	4-F-Ph	PIP	SO2	CH2	PhCH2CH2CH2CH2CH2	RH
67	68	450	4-F-Ph	PIP	SO2	CH2	2-CH3PhCH2CH2	RH
75	76	450	4-F-Ph	Piperidinyl	SO2	CH2	3-PyridylCH(CH3)CH2	RH
69	70	510-512	4-Br-Ph	PIP	SO2	CH2	PhCH(CH3)CH2	RH
133	135	346	4-F-Ph	PIP	SO2	CH2	CH3	RH
		465	4-F-Ph	PIP	SO2	CH2	CH2CH2CH(CH3)3-Pyr	RH
60	63	450	4-F-Ph	PIP	SO2	CH2	CH(CH3)CH2Ph	RH
		478	4-F-Ph	PIP	SO2	CH2	CH2CH(Pri)Ph	RH
		452	4-F-Ph	PIP	SO2	CH2	CH2CH(CH3)Pyrazinyl	RH


Mp Low	Mp High	M+H	B	A	Y	Q	R1	Z
		420	2-Pyrimidinyl	PIP	SO2	CH2	PhCH2CH2	RH
155	157	454	6-Cl-4-Pyrimidinyl	PIP	SO2	CH2	PhCH2CH2	RH
		452	4-Cl-Ph	PIP	SO2	CH2	PhCH2CH2	RH
		452	3-Cl-Ph	PIP	SO2	CH2	PhCH2CH2	RH
		486	3,4-di-Cl-Ph	PIP	SO2	CH2	PhCH2CH2	RH
		453	5-Cl-2-Pyridyl	PIP	SO2	CH2	PhCH2CH2	RH
		453	3-Cl-2-Pyridyl	PIP	SO2	CH2	PhCH2CH2	RH
		466	4-Cl-Ph	Homopiperazine	SO2	CH2	PhCH2CH2	RH
		419	2-Pyridyl	PIP	SO2	CH2	PhCH2CH2	RH
		494	6-Cl-4-Pyrimidinyl	PIP	SO2	CH2	3,4-di-Cl-Ph	RH
		450	6-MeO-4-Pyrimidinyl	PIP	SO2	CH2	PhCH2CH2	RH
118	120	470	6-Cl-4-Pyrimidinyl	PIP	SO2	CH2	PhCH2OCH2	RH
		493	6-Cl-2-Pyridyl	PIP	SO2	CH2	3,4-di-Cl-Ph	RH
		527	5-CF3-2-Pyridyl	PIP	SO2	CH2	3,4-di-Cl-Ph	RH
		562	3-Cl-5-CF3-2-Pyridyl	PIP	SO2	CH2	3,4-di-Cl-Ph	RH
		469	5-Cl-2-Pyridyl	PIP	SO2	CH2	PhCH2OCH2	RH
		493	5-Cl-2-Pyridyl	PIP	SO2	CH2	3,4-di-Cl-Ph	RH
		494	6-Cl-4-Pyrimidinyl	PIP	SO2	CH2	4-CF3-Ph	RH
		523	4-Me-2-quinolyl	PIP	SO2	CH2	3,4-di-Cl-Ph	RH
		468	3-Cl-Ph	PIP	SO2	CH2	PhCH2OCH2	RH
		454	2-Cl-4-Pyrimidinyl	PIP	SO2	CH2	PhCH2CH2	RH
		459	2-Benzoxazolyl	PIP	SO2	CH2	PhCH2CH2	RH
		475	2-Benzthiazolyl	PIP	SO2	CH2	PhCH2CH2	RH
		454	6-Cl-3-Pyridazinyl	PIP	SO2	CH2	PhCH2CH2	RH

Mp Low	Mp High	M+H	B	A	Y	Q	R1	Z
		460	2-Pyridyl	PIP	SO2	CH2	3,4-di-Cl-Ph	RH
		459	2-Pyridyl	PIP	SO2	CH2	4-CF3-Ph	RH
		435	2-Pyridyl	PIP	SO2	CH2	PhCH2OCH2	RH
		420	2-Pyridyl	PIP	SO2	CH2	2-PyridylCH2CH2	RH
		509	7-Cl-2-Benzthiazolyl	PIP	SO2	CH2	PhCH2CH2	RH
		461	2-Pyrazinyl	PIP	SO2	CH2	3,4-di-Cl-Ph	RH
		460	2-Pyrazinyl	PIP	SO2	CH2	4-CF3-Ph	RH
		436	2-Pyrazinyl	PIP	SO2	CH2	PhCH2OCH2	RH
		421	2-Pyrazinyl	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		420	2-Pyrazinyl	PIP	SO2	CH2	PhCH2CH2	RH
		470	6-Cl-3-Pyridazinyl	PIP	SO2	CH2	PhCH2OCH2	RH
136	138	420	4-Pyrimidinyl	PIP	SO2	CH2	PhCH2CH2	RH
		421	2-Pyrazinyl	PIP	SO2	CH2	2-PyridylCH2CH2	RH
		417	5-Cl-2-Pyridyl	PIP	SO2	CH2	c-Pentyl	RH
		484	5-CN-2-Pyridyl	PIP	SO2	CH2	3,4-di-Cl-Ph	RH
		494	6-Cl-2-Benzoxazolyl	PIP	SO2	CH2	2-PyridylCH2CH2	RH
			4-F-Ph	PIP	SO2	CH2	2-Furyl	RH
		437	4-F-Ph	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		437	4-F-Ph	PIP	SO2	CH2	4-PyridylCH2CH2	RH
		492	4-F-Ph	PIP	SO2	CH2	PhCH2CH2CH2C (Me)2	RH
		470,472	4-F-Ph	PIP	SO2	CH2	4-Cl-PhCH2CH2	RH
		450	4-F-Ph	PIP	SO2	CH2	PhCH2CH2CH2	RH
		426	4-F-Ph	PIP	SO2	CH2	2-FurylCH2CH2	RH
		456	4-F-Ph	PIP	SO2	CH2	2-Thiophenyl- CH2CH2CH2	RH
		468	4-F-Ph	PIP	SO2	CH2	4-F- PhCH2CH2CH2	RH
		454	4-F-Ph	PIP	SO2	CH2	4-F-PhCH2CH2	RH
		437	4-F-Ph	PIP	SO2	CH2	2-PyridylCH2CH2	RH
		509,511	5-Cl-2-Pyridyl	PIP	SO2	CH2	4-Br-2-Thiophenyl	RH
		420	2-Pyridyl	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		453,455	3-Cl-Ph	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		487,489	3,4-di-Cl-Ph	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		464	4-F-Ph	PIP	SO2	CH2	PhCH2CH2CH2C H2	RH
		454,456	5-Cl-2-Pyridyl	PIP	SO2	CH2	3-PyridylCH2CH2	RH

Mp Low	Mp High	M+H	B	A	Y	Q	R1	Z
		466,468	3-Cl-Ph	PIP	SO2	CH2	PhCH2CH2CH2	RH
		467,469	5-Cl-2-Pyridyl	PIP	SO2	CH2	PhCH2CH2CH2	RH
		468,470	6-Cl-4-Pyrimidinyl	PIP	SO2	CH2	PhCH2CH2CH2	RH
		455,457	2-Cl-4-Pyrimidinyl	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		455,457	6-Cl-4-Pyrimidinyl	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		454,456	3-Cl-2-Pyridyl	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		433	2-Pyridyl	PIP	SO2	CH2	PhCH2CH2CH2	RH
		503	5-CF3-2-Pyridyl	PIP	SO2	CH2	PhCH2OCH2	RH
		468,470	P2-Cl-4-Pyrimidinyl	PIP	SO2	CH2	PhCH2CH2CH2	RH
		453,455	3-Cl-Ph	PIP	SO2	CH2	2-PyridylCH2CH2	RH
		487,489	3,4-di-Cl-Ph	PIP	SO2	CH2	2-PyridylCH2CH2	RH
135	137	455,457	6-Cl-4-Pyrimidinyl	PIP	SO2	CH2	2-PyridylCH2CH2	RH
107	109	488	5-CF3-2-Pyridyl	PIP	SO2	CH2	2-PyridylCH2CH2	RH
		451	4-F-Ph	PIP	SO2	CH2	2-PyridylCH2CH2CH2	RH
120	123	452	4-F-Ph	PIP	SO2	CH2	2-PyrimidinylCH2CH2CH2	RH
		452	4-F-Ph	PIP	SO2	CH2	5-PyrimidinylCH2CH2CH2	RH
119	121	468	5-Cl-2-Pyridyl	PIP	SO2	CH2	2-PyridylCH2CH2CH2	RH
		469,471	5-Cl-2-Pyridyl	PIP	SO2	CH2	5-PyrimidinylCH2CH2CH2	RH
131	134	469,471	5-Cl-2-Pyridyl	PIP	SO2	CH2	2-PyrimidinylCH2CH2CH2	RH
		426,428	5-Cl-2-Pyridyl	PIP	SO2	CH2	2-Pyridyl	RH

MS for C₁₇H₂₄FN₃O₅S (M+H) calcd 402, found 402.

5



The aryl/heteroaryl piperazines and piperidines used as starting materials were commercially available or were described in the literature, for example

4-(4-fluorophenyl)-piperidine, CAS number 37656-48-7

Piperazine, 1-[1,1'-biphenyl]-4-yl-(180698-19-5)

5 Piperazine, 1-[1,1'-biphenyl]-3-yl- (115761-61-0)

Piperazine, 1-(2-naphthalenyl)- (57536-91-1)

Piperazinone, 1-phenyl-(90917-86-5)

1H-1,4-Diazepine, 1-(4-chlorophenyl)hexahydro-(41885-98-7)

Quinoline, 4-methyl-2-(1-piperazinyl)- (50693-78-2)

10 Piperazine, 1-(4-phenoxyphenyl)- 62755-61-7

Piperazine, 1-(3-chlorophenyl)-

The 2-methyl-4-(4-fluorophenyl)-piperazine used as starting material was prepared as follows:

Sodium-t-butoxide (4.1g) was added to a solution of tri-tolylphosphine (0.638g) and
15 palladium acetate (0.319g) in toluene (250 mL) under argon and the mixture was stirred for 20 minutes. 4-Fluoro-bromobenzene (5g) and 2-methylpiperazine (2.85g) were added and the mixture was heated at 110 °C for 7 hours, then allowed to cool to ambient temperature and keep at this temperature for 20 hours. The reaction mixture was filtered through Celite®, the filter cake was washed twice with dichloromethane (2X25 mL) and the filtrate
20 was evaporated to dryness. The residue was chromatographed on silica eluting initially with dichloromethane and then with a mixture of dichloromethane, methanol and ammonium hydroxide (100:5:1) to give 2-methyl-4-(4-fluorophenyl)-piperazine, 2.5g.

Using this same method and 2,6-dimethylpiperazine as starting material there was obtained 2,6-dimethyl-4-(4-fluorophenyl)-piperazine.

25 Piperazine, 1-[1,1'-biphenyl-4'-fluoro]-4-yl hydrochloride


tert-butoxycarbonyl piperazine, 1-[1,1'-biphenyl-4'-fluoro]-4-yl (0.712g) was stirred in a mixture of dichloromethane (10ml) and trifluoroacetic acid (1.0ml) for 18 hours at ambient temperature, evaporated in vacuo to a grey solid and used without further purification. The tert-butoxycarbonyl piperazine, 1-[1,1'-biphenyl-4'-fluoro]-4-yl used as starting material
30 was prepared as follows:

Sodium-t-butoxide (1.35g) was added to a solution of S-(-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (0.046g) and bis(dibenzylideneacetone)palladium

(0.023g) in toluene (25 ml) under argon and then added 4-bromo-4'-fluorobiphenyl (2.51g) and 1-tert-butoxycarbonylpiperazine (2.2g) and the mixture was heated at 80°C for 5 hours. The reaction mixture was filtered, filtrate evaporated in vacuo to a yellow solid which was triturated and then filtered from diethyl ether (20 ml) to give tert-butoxycarbonyl piperazine, 1-[1,1'-biphenyl-4'-fluoro]-4-yl, (2.67g), mp 165-166 °C.

NMR (d6-DMSO) 1.42 (s, 9H), 3.15 (m, 4H), 3.48 (m, 4H), 7.02 (d, 2H), 7.22 (m, 2H), 7.51 (d, 2H), 7.63 (m, 2H); m/z 357(M+1).


Example 13



Acetic anhydride (0.23ml) was added directly to formic acid (0.9ml). The solution was stirred at room temperature for 30 minutes and then added a solution of N-[2-{[4-(6-chloropyrimidin-4-yl)tetrahydropyrazin-1-yl]sulfonyl}-1-(3,4-dichlorophenyl)ethyl]hydroxylamine (0.227g) in tetrahydrofuran (5ml). The solution was stirred at room temperature for 18 hours. The solution was evaporated (water-bath temperature 30 °C) and the residual gum was purified by chromatography using a 10g silica

isolute eluting with CH₂Cl₂-3% Methanol/CH₂Cl₂ to give N-[2-{[4-(6-chloropyrimidin-4-yl)piperazino]sulfonyl}-1-(3,4-dichlorophenyl)ethyl]-N-hydroxyformamide (0.178g), 98-101°C.


NMR (d6-DMSO 373 °K): 3.31 (m, 4H), 3.70 (dd, 1H), 3.75 (m, 4H), 3.95 (dd, 1H), 5.61 (vbs, 1H), 6.89 (s, 1H), 7.43 (dd, 1H), 7.60 (d, 1H), 7.70 (d, 1H), 8.29 (s, 1H), 8.36 (s, 1H); m/z 494 (M+1).



-48-

Acetic anhydride (0.63ml) was added directly to formic acid (2.48ml). The solution was stirred at room temperature for 30 minutes and then added a solution of N-[2-{[4-(5-chloropyridin-2-yl)piperazino]sulfonyl}-1-(3,4-dichlorophenyl)ethyl]hydroxylamine (0.61g) in tetrahydrofuran (10ml). The solution was stirred at room temperature for 3 hours and then diluted with ethyl acetate, neutralised the pH with saturated aqueous sodium hydrogen carbonate solution. The ethyl acetate layer was separated, dried (Na₂SO₄), and evaporated to dryness. The residue was purified by chromatography using a 10g silica isolate eluting with 10% ethyl acetate/hexane-80% ethyl acetate/hexane and then evaporated to dryness. The resulting white solid was filtered from diethyl ether to give N-[2-{[4-(5-chloropyridin-2-yl)piperazino]sulfonyl}-1-(3,4-dichlorophenyl)ethyl]-N-hydroxyformamide (0.431g), 211-212°C.


NMR (d₆-DMSO 373 °K): 3.30 (m, 4H), 3.80 (m, 4H), 3.85 (dd, 1H), 3.95 (dd, 1H), 5.58 (vbs, 1H), 6.85 (d, 1H), 7.43 (m, 1H), 7.58 (m, 2H), 7.85 (d, 1H), 8.10 (d, 1H), 8.13 (s, 1H); m/z 493 (M+1).



Acetic anhydride (0.48ml) was added directly to formic acid (1.9ml). The solution was stirred at room temperature for 30 minutes and then added a solution of N-(2-(benzyloxy)-1-{[(4-pyridin-2-yl)piperazino]sulfonyl}methyl)ethyl)hydroxylamine (0.42g) in tetrahydrofuran (5ml). The solution was stirred at room temperature for 3 hours and then diluted with ethyl acetate, neutralised the pH with saturated aqueous sodium hydrogen carbonate solution. The ethyl acetate layer was separated, dried (Na₂SO₄), and evaporated to dryness. The residue was purified by chromatography using a 10g silica isolate eluting with CH₂Cl₂ 25% Methanol/CH₂Cl₂ to give N-(2-(benzyloxy)-1-{[(4-pyridin-2-yl)piperazino]sulfonyl}methyl)ethyl)-N-hydroxyformamide (0.233g), 70-75 °C.

NMR (d₆-DMSO 373 °K): 3.25 (dd, 1H), 3.31 (m, 4H), 3.48 (dd, 1H), 3.65 (m, 4H), 3.66 (dd, 1H), 3.70 (dd, 1H), 4.55 (vbs, 1H), 4.55 (s, 2H), 6.70 (m, 1H), 6.85 (d, 1H), 7.28 (m, 1H), 7.32 (m, 4H), 7.58 (m, 1H), 8.17 (m, 2H), 9.45 (bs, 1H); m/z 435 (M+1).

-49-




Acetic anhydride (0.48ml) was added directly to formic acid (1.9ml). The solution was stirred at room temperature for 30 minutes and then added a

- 5 solution of N-(3-pyridin-2-yl-1-[[4-(pyridin-2-yl)piperazino)sulfonyl]methyl-propyl)hydroxylamine (0.152g) in tetrahydrofuran (5ml). The solution was stirred at room temperature for 3 hours and then diluted with ethyl acetate, neutralised the pH with saturated aqueous sodium hydrogen carbonate solution. The ethyl acetate layer was separated, dried (Na₂SO₄), and evaporated to dryness. The residue was purified by chromatography using a
- 10 10g silica isolate eluting with CH₂Cl₂/25% Methanol/CH₂Cl₂ to give N-hydroxy-N-(3-pyridin-2-yl-1-[[4-(pyridin-2-yl)piperazino)sulfonyl]methyl]propyl)formamide (0.039g), 80-84 °C NMR (d₆-DMSO 373 °K): 2.10 (m, 2H), 2.80 (m, 2H), 3.25 (dd, 1H), 3.30 (m, 4H), 3.50 (dd, 1H), 3.60 (m, 4H), 4.42 (vbs, 1H), 6.70 (m, 1H), 6.85 (d, 1H), 7.19 (m, 1H), 7.22 (d, 1H), 7.54 (m, 1H), 7.65 (m, 1H), 8.10 (vbs, 1H), 8.15 (m, 1H), 8.45 (m, 1H), 9.50 (vbs, 1H); m/z 420 (M+1).
- 15

Example 14

N-{1-[[4-[(5-chloropyridin-2-yl)oxy]piperidino]sulfonyl]methyl]-3-pyridin-3-ylpropyl}-N-hydroxyformamide

20



- To a solution of 1-N-[2-(hydroxyamino)-2-(3-pyridinyl)butanesulfonyl]-4-O-(5-chloro-2-pyridinyl)piperidine (2.1 g, 4.18 mmol) in THF (36 ml) added a preformed mixture of formic acid (9.0 ml) and acetic anhydride (2.25 ml). The mixture was stirred at room
- 25 temperature for 18 hrs. The reaction was neutralised using saturated aqueous NaHCO₃ before extracting the solution with EtOAc (x2). The combined organics were dried over Na₂SO₄ and evaporated in vacuo. The residue was stirred in MeOH at room temperature for

20 hrs to remove the bis-formyl. The residue was crystallised from EtOH to afford a white solid (0.898g). m.p. 130-140°C.

¹H NMR (DMSO-100°C) : 9.50 (br s, 1H), 8.43 (d, 1H), 8.39 (dd, 1H), 8.15 (d, 1H), 8.13 (br s, 1H), 7.74 (dd, 1H), 7.60 (m, 1H), 7.27 (m, 1H), 6.83 (d, 1H), 5.12 (m, 1H), 4.32 (br s, 1H), 3.42 (m, 3H), 3.16 (m, 3H), 2.68-2.54 (m, 2H), 2.06-1.93 (m, 4H), 1.76 (m, 2H); MS (ES+): 469.2 (MH⁺), 491.1 (MNa⁺); EA: calculated for C₂₀H₂₅ClN₄O₅S: C 51.22, H 5.37, Cl 7.56, N 11.95, S 6.84, Found: C 50.92, H 5.30, Cl 7.55, N 11.90, S 6.75.

The starting material was prepared as follows :

i) NaH (2.88g, 66mmol, 55% dispersion in mineral oil) was stirred in dry DME (200ml), under Argon. A mixture of 2,5- dichloropyridine (8.87g, 60mmol) and 4-hydroxypiperidine (6.67g, 66mmol) dissolved in dry DME (200ml) was added to the NaH suspension dropwise, over a period of 30 minutes. After complete addition the reaction is heated to 82°C for 48 hrs, maintaining the Argon blanket. The reaction was slowly quenched with water before removing most of the THF. Extracted the aqueous with DCM (x3). The organic layers were dried with Na₂SO₄ and evaporated in vacuo to afford 2-(4-piperidinyloxy) -5-chloropyridine as a yellow oil (12.7g, quantitative). ¹H NMR (DMSO): 8.17 (d, 1H), 7.76 (dd, 1H), 6.81 (d, 1H), 4.96 (m, 1H), 2.93 (m, 2H), 2.53 (m, 2H), 1.91 (m, 2H), 1.46 (m, 2H); MS (ES+): 213.3 (MH⁺), 225.3 (MNa⁺)

ii) To a solution 2-(4-piperidinyloxy) -5-chloropyridine (12.9 g, 0.06 mol) and Et₃N (25.4 ml, 0.182 mol) in dry dichloromethane (400 ml) at 0°C and under Argon, was added methanesulfonyl chloride (5.3 ml, 0.067 mol) in dry dichloromethane (100 ml), dropwise. The mixture was stirred for 20 hours at room temperature. The mixture was diluted with dichloromethane (250 ml), then washed with water (x3) then brine. The organic layers were dried with Na₂SO₄ and evaporated in vacuo. The residue was triturated and washed with diethylether to give 2-(N-methanesulfonyl-4-piperidinyloxy) -5-chloropyridine (15.1 g) as a pale yellow solid.

¹H NMR (DMSO): 8.20 (d, 1H), 7.81 (dd, 1H), 6.87 (d, 1H), 5.09 (m, 1H), 3.32 (m, 2H), 3.11 (m, 2H), 2.90 (s, 3H), 2.02 (m, 2H), 1.75 (m, 2H); MS (ES+): 291.2 (MH⁺), 313.2 (MNa⁺).

iii) 2-(N-methanesulfonyl-4-piperidinyloxy) -5-chloropyridine (2.0g, 6.89 mmol) was taken into anhydrous THF (100 ml) under Argon then cooled to -78°C before the addition of Li(TMSA) (13.8 ml of a 1.0M solution in THF, 13.8 mmol), . The mixture was stirred at -78°C for 20 minutes and a solution of diethylchlorophosphate (1.05 ml, 7.23 mmol) was added. The


-51-

mixture was stirred at -78°C for 1 hour before 3-pyridinylpropanal (1.12g, 8.27 mmol) was added then stirred at -78 for a further 1 hr. The mixture was allowed to warmed to room temperature then was washed with aqueous ammonium chloride and extracted with ethyl acetate. The organic layers were washed with water, brine and dried over Na_2SO_4 . Purification of the residue on silica (eluant : gradient, DCM - 2% MeOH/DCM) afforded 2-{N-[E/Z-4(3-pyridyl)-but-1-enyl] sulfonyl}4-piperidinyloxy) -5-chloropyridine as a yellow oil (2.09g).

^1H NMR (DMSO): 8.45 (m, 1H), 8.37 (m, 1H), 8.19 (m, 1H), 7.82 (m, 1H), 7.64 (m, 1H), 7.30 (m, 1H), 6.85 (m, 1H), 6.88-6.27 (m, 2H, E/Z isomers), 5.00 (m, 1H), 3.15 (m, 2H), 2.83 (m, 5H), 2.61 (m, 1H), 1.85 (m, 2H), 1.70 (m, 2H); MS (ES $^{+}$): 408.1 (MH^{+}), 430.2 (MNa^{+}).

iv) To a solution of 2-{N-[E/Z-4(3-pyridyl)-but-1-enyl] sulfonyl}4-piperidinyloxy) -5-chloropyridine(2.09 g, 5.1 mmol) in THF (20 ml) was added hydroxylamine (3.4 ml, 50 % aqueous solution). The mixture was stirred for 18 hours. The solvent was evaporated. The residue was dissolved in EtOAc and washed with water (x4). The organic layer was dried on Na_2SO_4 and evaporated in vacuo to give 2-(4-piperidinyloxy) -5-chloropyridine 1-N-[2-(hydroxyamino)-2-(3-pyridinyl)butanesulfonyl]-4-O-(5-chloro-2-pyridinyl)piperidine (730 mg). ^1H NMR (DMSO): 8.43 (d, 1H), 8.37 (dd, 1H), 8.18 (d, 1H), 7.78 (dd, 1H), 7.61 (m, 1H), 7.36 (s, 1H) , 7.29 (m, 1H), 7.85 (d, 1H), 5.70 (s, 1H), 5.08 (m, 1H), 3.35 (m, 3H), 3.16-3.00 (br m, 4H), 2.80-2.60 (br m, 2H), 1.98 (m, 2H), 1.84 (m, 2H), 1.69 (m, 2H); MS (ES $^{+}$): 441.2 (MH^{+}), 463.2 (MNa^{+}).

Using an analogous procedure to that described in Example X, a aryl-4-O-piperidine was reacted with the appropriate aldehyde to give the compounds listed below.



R1	R2	R3	MW	MS (ES $^{+}$)
Ph	H	4-chlorophenyl	438	439
PhCH ₂ CH ₂	H	3-chlorophenyl	466.99	468
PhCH ₂ CH ₂	H	3,4-dichlorophenyl	501.43	501
PhCH ₂ CH ₂	H	4-chlorophenyl	466.99	468
PhCH ₂ CH ₂	H	5-chloro-2-pyridyl	467.98	468
PhCH ₂ CH ₂	H	6-chloro-4-pyrimidinyl	468.96	469

Methyl	Methyl	5-chloro-2-pyridyl	391.88	392
PhCH ₂ CH ₂	H	2-pyridyl	433.53	434
3-pyridyl	H	5-chloro-2-pyridyl	440.91	441
3-pyridylCH ₂ CH ₂	H	5-chloro-2-pyridyl	468.96	469
2-pyridylCH ₂ CH ₂	H	5-chloro-2-pyridyl	468.96	469
PhCH ₂ OCH ₂	H	5-chloro-2-pyridyl	483.97	484

The following aryl-4-O-piperidines have been described previously:

Piperidine, 4-(3-chlorophenoxy)-(9Cl), CAS (97840-40-9)

5 Piperidine, 4-(4-chlorophenoxy)-(9Cl), CAS (97839-99-1)

Pyridine, 2-(4-piperidinyloxy)-(9Cl), CAS (127806-46-6)

Piperidine, 4-(3,4-dichlorophenoxy)-(9Cl) was synthesised in the following alternative route:-

1) To a stirred solution 4-hydroxypiperidine(3.5 g, 0.035 mol) in dry methanol (50 ml) at 0°C, was added di-^tbutyl dicarbonate (9.2 ml, 0.042 mol) in dry methanol (50 ml), dropwise.

10 The mixture was stirred for 20 hours at room temperature. The methanol was removed and the remaining solution was taken into Et₂O, then washed with 1M citric acid (x3) and water (x3). The combined aqueous extracts were extracted with Et₂O which was dried with Na₂SO₄ and evaporated in vacuo. Purification of the residue on silica (eluant : gradient, DCM - 30% MeOH/DCM) afforded N-BOC-4-hydroxypiperidine as a yellow oil (6.4g). ¹H NMR

15 (DMSO): 4.05 (m, 2H), 3.70-3.52 (br m, 3H), 2.92 (m, 2H), 1.66 (m, 2H), 1.40 (s, 9H), 1.33-1.18 (br m, 2H); MS (ES⁺): 201.3 (MH⁺), 219.4 (MNH₄⁺).

2) To a stirred solution N-BOC-4-hydroxypiperidine(2.0 g, 0.01 mol), triphenylphosphine (3.68g, 0.014 mol) and 3,4-dichlorophenol (1.96g, 0.012 mol) in dry toluene (75 ml) [with molecular sieves, at 0°C and under Argon] was added diethyl azodicarboxylate (2.52 ml,

20 0.016 mol), dropwise. The mixture was stirred for 1.5hrs at 0°C. Filtered the solution and removed the toluene before vigorously stirring in isohexane (100ml) and filtered the resulting suspension. The filtrate was washed with 2M aqueous NaOH (x8), dried with Na₂SO₄ and evaporated in vacuo. Purification of the residue on silica (eluant : 20% EtOAc/isohexane) afforded N-Boc-Piperidine, 4-(3,4-dichlorophenoxy)-(9Cl) as a yellow solid (1.96g). ¹H NMR

25 (DMSO): 7.52 (d, 1H), 7.31 (d, 1H), 7.01 (dd, 1H), 4.62 (m, 1H), 3.65 (m, 2H), 3.15 (m, 2H), 1.88 (m, 2H), 1.53 (m, 2H), 1.40 (s, 9H); MS (ES⁺): 346.3 (MH⁺), 368.4 (MNa⁺).

3) 50% aqueous trifluoroacetic acid (18ml) was added to a stirred solution N-Boc-piperidine, 4-(3,4-dichlorophenoxy)-(9Cl) (1.96 g, 5.66 mmol). After 3.5hrs toluene is added and evaporated in vacuo, this was repeated twice. The residue was then taken into EtOAc

washed with saturated aqueous NaHCO_3 (x3), dried with Na_2SO_4 and evaporated in vacuo to afforded piperidine, 4-(3,4-dichlorophenoxy)-(9Cl) a white solid (1.3g). ^1H NMR (DMSO): 7.54 (d, 1H), 7.35 (d, 1H), 7.04 (dd, 1H), 4.70 (m, 1H), 3.31 (m, 2H), 3.09 (m, 2H), 2.08 (m, 2H), 1.80 (m, 2H); MS (ES⁺): 2.26.3 (MH⁺).


- 5 Piperidine, 4-(3,4-dichlorophenoxy)-(9Cl) was then taken through steps ii-iv as described above.

Example 15

1-Mesyl-4-(5-methoxycarbonyl-2-pyridyl)piperazine

- 10 1-Mesylpiperazine hydrochloride (4.24g) was added to a solution of methyl 6-chloronicotinate (1.7g) and N,N-diisopropylethylamine (6.3ml) in dimethylacetamide (20ml) and the mixture was heated at 120°C for 2 hours. The mixture was allowed to cool to ambient temperature and poured onto crushed ice/water (50ml) to precipitate a tan solid. The solid was collected by filtration and dried at 80 °C for 18 hours in a vacuum oven, to give 1-
- 15 mesyl-4-(5-methoxycarbonyl-2-pyridyl)piperazine (2.05g), mp 205-207°C.
- NMR (d6-DMSO): 2.90 (s, 3H), 3.20 (m, 4H), 3.78 (m, 3H), 3.80 (s, 3H), 6.92 (d, 1H), 8.00 (dd, 1H), 8.67 (d, 1H); m/z 300 (M+1).

- 20 Using an analogous procedure 1-mesylpiperazine hydrochloride, CAS(161357-89-7), was reacted with the appropriate chloropyridine to give the following compounds.



R	MW	m/z (M+1).
6-Cl-2-pyridyl	275	276
5-Cl-2-pyridyl	275	276
5-CF ₃ -2-pyridyl	309	310
3-Cl-5-CF ₃ -2-pyridyl	343	344
5-CN-2-pyridyl	266	267
3-Cl-2-pyridyl	275	276
5-Br-2-pyridyl		320/322

1-(6-chloropyrimidin-4-yl)-4- mesylpiperazine


A mixture of 4,6-dichloropyrimidine (39.4g), 1-mesylpiperazine hydrochloride (55.7g) and triethylamine (116ml) in ethanol (500ml) was stirred at reflux temperature for 4 hours.

The mixture was then stirred at room temperature for 12 hours. The solid, which had

5 separated, was collected by filtration, slurry washed with ethanol (2x80ml, 160ml) then with diethyl ether (150ml), and dried to give 1-(6-chloropyrimidin-4-yl)-4- mesylpiperazine as a cream solid (71.9g). mp 200-202°C


NMR (d6-DMSO): 2.88 (s, 3H), 3.18 (m, 4H), 3.80 (m, 4H), 7.04 (s, 1H), 8.38 (m, 1H);
m/z 277.3 (M+1).

10 Using an analogous procedure 1-mesylpiperazine hydrochloride, CAS(161357-89-7), was reacted with the appropriate chloropyrimidine or chloropyridazine to give the following compounds.



15

R	MW	m/z (M+1).
2-Cl-pyrimidin-4-yl	276	277
6-Cl-pyridazin-3-yl	276	277
pyrimidin-4-yl	242	243
6-methoxy-pyrimidin-4-yl		273.1


Example 16

Acetic anhydride (19ml) was added directly to formic acid (76ml). The solution was
20 stirred at room temperature for 30 minutes. A solution of 1-(6-chloropyrimidin-4-yl)-4-{[2-(hydroxyamino)-4-phenylbutyl]sulphonyl}piperazine (17.2g) in tetrahydrofuran (85ml) was

added in portions, to the above solution at 27 °C over 25 minutes. The solution was stirred at room temperature for 1 hour. The solution was evaporated (water-bath temperature 30°C) and the residual gum was dissolved in ethyl acetate (500ml). This solution was treated with saturated aqueous sodium hydrogen carbonate solution (200ml) and the mixture (pH8) was stirred at room temperature for 16 hours. The ethyl acetate layer was separated, washed with saturated brine (100ml), dried (Na₂SO₄), and evaporated to dryness. The residual foam was dissolved in ethanol, a solid separated and the mixture was stirred for 2 days. The solid was collected by filtration, slurry washed with diethyl ether (100ml), and dried to give N-[1-({4-(6-chloropyrimidin-4-yl)piperazino]sulphonyl}methyl)-3-phenylpropyl]-N-hydroxyformamide as a colourless solid (12.8g). mp 155-157°C.

Found C, 50.29, H, 5.29, Cl, 7.82, N, 15.31, and S, 6.82 %. C₁₉H₂₄ClN₅O₄S requires C, 50.27, H, 5.33, Cl, 7.81, N, 15.43, and S, 7.06 %.

NMR (d₆-DMSO 373°K): 1.93 (m, 1H), 2.03 (m, 1H), 2.57 (m, 1H), 2.65 (m, 1H), 3.20 (dd, 1H), 3.26 (t, 4H), 3.48 (dd, 1H), 3.74 (t, 4H), 4.3 (v br, 1H), 6.90 (s, 1H), 7.19 (m, 3H), 7.27 (m, 2H), 8.1 (br, 1H), 8.38 (s, 1H), 9.5 (s, 1H); m/z 454.2 (M+1).




Acetic anhydride (31.5ml) was added directly to formic acid (126ml). The solution was stirred at room temperature for 30 minutes.

A solution of 1-{{3-benzyloxy-2-(hydroxyamino)propyl}sulphonyl}-4-(6-chloropyrimidin-4-yl)piperazine (29.5g) in tetrahydrofuran (150ml) and formic acid (25ml), was added in portions to the above solution at 25 °C over 25 minutes. The solution was stirred at room temperature for 1 hour. The solution was evaporated (water-bath temperature 30°C) and the residual gum was dissolved in ethyl acetate (500ml). This solution was treated with saturated aqueous sodium hydrogen carbonate solution (2x250ml) and the mixture (pH8) was stirred at room temperature for 16 hours. The ethyl acetate layer was separated, washed with saturated brine (100ml), dried (Na₂SO₄), and evaporated to dryness. The residual foam was dissolved in methanol (70ml) and the solution was stirred for 16 hours. The solution was evaporated to dryness (water-bath temperature 30 °C). The residual foam was stirred in ethanol (250ml),

solid separated and the mixture was stirred for 18 hours. The solid was collected by filtration, slurry washed with diethyl ether (100ml), and dried to give N-[2-(benzyloxy)-1-({[4-(6-chloropyrimidin-4-yl)piperazino]sulphonyl)methyl}ethyl]-N-hydroxyformamide (25.5g). mp 118-120°C

5 Found C, 48.35, H, 5.09, Cl, 7.26, N, 14.73, and S, 6.78 %. $C_{19}H_{24}ClN_5O_5S$ requires C, 48.56, H, 5.15, Cl, 7.54, N, 14.90, and S, 6.82 %.

NMR (d6-DMSO 373 °K): 3.23 (dd, 1H), 3.30 (t, 4H), 3.46 (dd, 1H), 3.57 (dd, 1H), 3.67 (dd, 1H), 3.72 (t, 4H), 4.50 (s, 2H), 4.50 (m, 1H), 7.35 (m, 5H), 8.15 (br, 1H), 8.38 (s, 1H), 9.48 (br, 1H); m/z 470.2 (M+1).




Acetic anhydride (0.8ml) was added directly to formic acid (3.2ml). The solution was stirred at room temperature for 30 minutes.

15 A solution of 1-(5-chloro-2-pyridyl)-4-{[2-(hydroxyamino)-4-phenylbutyl]sulphonyl}piperazine (0.72g) in tetrahydrofuran (5ml) was added to the above solution at room temperature. The solution was stirred at room temperature for 2 days. The solution was evaporated (water-bath temperature 40°C).

20 The residue was dissolved in 5% methanol in dichloromethane. Silica (5g Merck 9385) was added to the solution, the mixture was stirred for 21 hours, and evaporated to dryness. The material (pre-adsorbed on the silica) was purified by chromatography on silica (Bond Elut 10g), using 0-3% methanol in dichloromethane as eluent, to give N-[1-({[4-(5-chloro-2-pyridyl)piperazino]sulphonyl)methyl}-3-phenylpropyl]-N-hydroxyformamide as an orange foam (0.17g).


25 NMR (d6-DMSO 373°K): 1.92 (m, 1H), 2.04 (m, 1H), 2.55 (m, 1H), 2.64 (m, 1H), 3.20 (dd, 1H), 3.27 (m, 4H), 3.47 (dd, 1H), 3.58 (m, 4H), 4.35 (v br, 1H), 6.88 (dd, 1H), 7.17 (m, 3H), 7.27 (m, 2H), 7.57 (dd, 1H), 8.10 (s, 1H), 8.10 (br, 1H), 9.5 (s, 1H); m/z 453.3 (M+1).

Example 17

5

To formic acid (31.5ml) at 0°C was added acetic anhydride (7.9ml). After 20 minutes this was added to the hydroxylamine (6.10g) dissolved in THF (80ml) and formic acid (40ml) and the resulting solution stirred overnight at room temperature. The solvent was removed under reduced pressure and the residue dissolved in DCM (500ml), washed with saturated sodium bicarbonate solution (2x500ml), dried and evaporated to dryness. To the residue dissolved in DCM (10ml) was added diethyl ether (100ml) to give the product as a white solid (5.60g) which was collected by filtration. Mpt 168-170°C. NMR DMSO-d₆ δ 10.2 (br s, 1H)*; 9.8 (br s, 1H)*; 8.7 (br s, 1H)*; 8.6 (br s, 1H)*; 8.5 (d, 1H); 8.3 (m, 1H); 8.1 (d, 1H); 7.9-7.8 (m, 1H); 7.6 (dd, 1H); 7.4 (dd, 1H); 6.9 (d, 1H); 5.8 (m, 1H)*; 5.5 (m, 1H)*; 4.1-3.6 (m, 2H); 3.6 (m, 4H); 3.2 (m, 4H). Anal. Calcd for C₁₇H₂₀ClN₅O₄S: C, 48.0; H, 4.7; Cl, 8.3; N, 16.5; S, 7.5. Found: C, 47.9; H, 4.7; Cl, 8.4; N, 16.3; S, 7.5. MS for C₁₇H₂₀ClN₅O₄S (M+H) calcd 426, found 426.

* rotameric signals

Step A


(1)

The oxime (31.05g) [Tetrahedron Letters 1994, 35, 1011] was dissolved in DCM (500ml) and 3-pyridinecarboxaldehyde (12.09g) was added followed by anhydrous


20

magnesium sulfate (13.6g). After 2 days stirring at room temperature more magnesium sulfate (13.6g) was added and stirring was continued for a further 3 days. The mixture was then filtered, the solvent evaporated and the residue triturated with diethyl ether to give the product (36.34g) as a white solid. Mpt 174-175°C. NMR CDCl₃ δ 9.0 (s, 1H); 8.9 (d, 1H); 8.7 (d, 1H); 7.7 (s, 1H); 7.4 (dd, 1H); 5.6 (s, 1H); 5.3 (d, 1H); 4.9 (dd, 1H); 4.6 (dd, 1H); 4.4 (ddd 1H); 4.2 (dd, 1H); 3.7 (dd, 1H); 1.5 (s, 3H); 1.4 (s, 3H); 1.4(s, 3H); 1.3 (s, 3H).

Step B




The methyl sulfonamide (14.30g) was dissolved in THF (500ml) and cooled to -10°C when lithium hexamethyldisylazide (78ml, 1.0M in THF) was added. After 30 minutes the solution was cooled to -78°C, and the nitrone (18.00g) dissolved in THF (350ml) was added, keeping the temperature below -65°C. The resulting solution was stirred for 3 hours at -78°C when it was quenched by the addition of brine (500ml) and the aqueous layer extracted with ethyl acetate (3x500ml). The combined organic layers were dried and evaporated to give a yellow solid which was triturated with ethyl acetate / isohexane (4:1) and then purified by flash column chromatography eluting with dichloromethane / methanol (97:3) to give **1** (16.40g) as a white solid. Mpt 209-211°C (dec). NMR CDCl₃ δ 8.6 (s, 1H); 8.4 (d, 1H); 8.1 (d, 1H); 7.8 (d, 1H); 7.5 (br s, 1H); 7.4 (dd, 1H); 7.3 (dd, 1H); 6.6 (d, 1H); 4.9 (d, 1H); 4.8 (s, 1H); 4.7-4.6 (m, 2H); 4.2-4.1 (m, 3H); 3.8 (dd, 1H); 3.6 (dd, 1H); 3.5-3.4 (m, 5H); 3.3-3.2 (m, 4H); 1.4 (s, 3H); 1.3 (s, 3H); 1.3 (s, 3H); 1.3 (s, 3H).

Step C

- 5 To a solution of hydroxylamine 2 (14.90g,) in ethanol (300ml) was added water (220ml) followed by O-benzylhydroxylamine hydrochloride (13.91g) and sodium bicarbonate (6.95g). Heating gave a solution which was stirred overnight at 80°C. The ethanol was removed under reduced pressure and the residue separated between water (500ml) and ethyl acetate (500ml). The aqueous layer was washed with ethyl acetate (2x500ml), and the
- 10 combined organic layers were dried and evaporated to give a residue which was triturated with dichloromethane (100ml) to give 3 (6.10g) as a white solid. The mother liquor was purified by flash column chromatography eluting with ethyl acetate followed by dichloromethane / methanol (96:4) to give further 3 (0.85g). Mpt 170-173°C. NMR
- 15 DMSO-d₆ δ 8.6 (s, 1H); 8.5 (d, 1H); 8.1 (d, 1H); 7.8 (d, 1H); 7.6 (dd, 1H); 7.6 (s, 1H); 7.3 (dd, 1H); 6.9 (d, 1H); 6.1 (br s, 1H); 4.3 (br s, 1H); 3.7-3.4 (m, 6H); 3.2-3.1 (m, 4H).

Example 18

The following compounds were made using the method outlined in Example 7



20

Mp Low	Mp High	M+H	B	A	Y	Q	R1	Z
		403	4-PhCH ₂	Piperidinyl	SO ₂	CH ₂	Ph	RH
		357	4-HCOO	Piperidinyl	SO ₂	CH ₂	Ph	RH
			PhNCO	Piperidinyl	SO ₂	CH ₂	Ph	RH
128	131	412	t-ButylNCO	Piperidinyl	SO ₂	CH ₂	Ph	RH

-60-

Mp Low	Mp High	M+H	B	A	Y	Q	R1	Z
122	124	446	PhCH ₂ NCO	Piperidinyl	SO ₂	CH ₂	Ph	RH
129	131	423	c-PentylNCO	Piperidinyl	SO ₂	CH ₂	Ph	RH
		390	Ph	PIP	SO ₂	CH ₂	Ph	RH
		420	4-MeO-Ph	PIP	SO ₂	CH ₂	Ph	RH
		435	4-NO ₂ -Ph	PIP	SO ₂	CH ₂	Ph	RH
		404	4-CH ₃ -Ph	PIP	SO ₂	CH ₂	Ph	RH
		424	2-Cl-Ph	PIP	SO ₂	CH ₂	Ph	RH
		420	2-OMe-Ph	PIP	SO ₂	CH ₂	Ph	RH
		424	3-Cl-Ph	PIP	SO ₂	CH ₂	Ph	RH
		458	3-CF ₃ -Ph	PIP	SO ₂	CH ₂	Ph	RH
		424	4-Cl-Ph	PIP	SO ₂	CH ₂	Ph	RH
		420	3-OMe-Ph	PIP	SO ₂	CH ₂	Ph	RH
		458	3,4-di-Cl-Ph	PIP	SO ₂	CH ₂	Ph	RH
		438	4-Cl-PhCH ₂	PIP	SO ₂	CH ₂	Ph	RH
		452	4-Cl-PhCO	PIP	SO ₂	CH ₂	Ph	RH
		472	4-F-PhSO ₂	PIP	SO ₂	CH ₂	Ph	RH
		436	5-NO ₂ -2-Pyridyl	PIP	SO ₂	CH ₂	Ph	RH
		432	PhCH ₂ CO	PIP	SO ₂	CH ₂	Ph	RH
		504	2-NaphthylSO ₂	PIP	SO ₂	CH ₂	Ph	RH
		467	4-Ph-Ph	PIP	SO ₂	CH ₂	Ph	RH
		392	2-Pyrazinyl	PIP	SO ₂	CH ₂	Ph	RH
		391	2-Pyridyl	PIP	SO ₂	CH ₂	Ph	RH
		396	Cyclohexyl	PIP	SO ₂	CH ₂	Ph	RH
		466	3-Ph-Ph	PIP	SO ₂	CH ₂	Ph	RH
		458	4-CF ₃ -Ph	PIP	SO ₂	CH ₂	Ph	RH
		467	4-Cl-PhNCO	PIP	SO ₂	CH ₂	Ph	RH
		440	2-Naphthyl	PIP	SO ₂	CH ₂	Ph	RH
		356	n-Propyl	PIP	SO ₂	CH ₂	Ph	RH
		448	4-Piperonyl-CH ₂ -	PIP	SO ₂	CH ₂	Ph	RH
		460	4-t-Butyl-PhCH ₂ -	PIP	SO ₂	CH ₂	Ph	RH
55	60	439	4-Cl-PhO	Piperidinyl	SO ₂	CH ₂	Ph	RH
		391	4-Pyridyl	PIP	SO ₂	CH ₂	Ph	RH
		484	4'-F-4-Ph-Ph	PIP	SO ₂	CH ₂	Ph	RH
		482	4-Ph-O-Ph	PIP	SO ₂	CH ₂	Ph	RH
		404	4-Ph	3-OxoPIP	SO ₂	CH ₂	Ph	RH
		449	5-CO ₂ Me-Pyridyl	PIP	SO ₂	CH ₂	Ph	RH
		501	2-PyridylNCO	Piperidinyl	SO ₂	CH ₂	3,4-di-Cl-Ph	RH
		535	5-Cl-2-PyridylNCO	Piperidinyl	SO ₂	CH ₂	3,4-di-Cl-Ph	RH
		534	4-Cl-PhNCO	Piperidinyl	SO ₂	CH ₂	3,4-di-Cl-Ph	RH
		500	PhNCO	Piperidinyl	SO ₂	CH ₂	3,4-di-Cl-Ph	RH

* = M-H

R2 = hydrogen

PIP = piperazinyl

RH = reverse hydroxamate





The starting material was prepared as follows:

The addition of hydroxylamine to 1-trans- β -styrenesulphonyl-piperidine-4-(N-phenylcarboxamide) and the subsequent formylation of the product was carried out as described in Example 7.

- 5 Dimethylformamide (2 drops) was added to a suspension of 1-trans- β -styrenesulphonyl-piperidine-4-carboxylic acid (0.75g) and oxalyl chloride (0.23 mL) in dichloromethane (10 mL) and was stirred for 2 hours. The reaction mixture was evaporated to dryness, re-dissolved in dichloromethane (10 mL) and evaporated to dryness again. The residue obtained was dissolved in dichloromethane (4 mL) and a mixture of aniline (0.23 mL)
- 10 and triethylamine (0.35 mL) was added dropwise. The mixture was stirred for 20 hours and was washed with dilute 2M hydrochloric acid, water, aqueous saturated sodium bicarbonate solution and water and dried. Removal of the solvent gave 1-trans- β -styrenesulphonyl-piperidine-4-(N-phenylcarboxamide), 0.89g

Using the method described above there were prepared the following

- 15 1-trans- β -styrenesulphonyl-piperidine-4-carboxamides

	438	437(M-1)
	439	440(M+1)
	473	472(M-1)
	472	471(M-1)

A solution of ethyl piperidine-4-carboxylate (3.99g) in a mixture of THF (30 mL) and methanol (6 mL) was treated with aqueous sodium hydroxide solution (20 mL of 2M NaOH) and the mixture stirred for 3 hours, evaporated to small volume and acidified to pH 5 with dilute 2M hydrochloric acid. The mixture obtained was extracted with ethyl acetate (2x25 mL), the ethyl acetate extracts were washed with water, dried and evaporated to dryness to give 1-trans- β -styrenesulphonyl-piperidine-4-carboxylic acid, 2.64 g.


A solution of ethyl piperidine-4-carboxylate (3.0 mL) and triethylamine (2.7 mL) in dichloromethane (10 mL) was added dropwise to a cooled (ice bath) solution of trans- β -styrenesulphonyl chloride (3.95g) in dichloromethane (10 mL). The reaction mixture was allowed to warm to ambient temperature and stirring was continued for 20 hours. The reaction mixture was evaporated to dryness, the residue was diluted with water and extracted with ethyl acetate (2x25 mL). The combined ethyl acetate extracts were washed with brine and dried (MgSO₄) to give ethyl -(1-trans- β -styrenesulphonyl)-piperidine-4-carboxylate 5.76g, M+H = 324.

An alternative procedure for the preparation of 1-trans- β -3,4dichlorostyrenesulphonyl-piperidine-4-carboxylic acid may be used:

To a solution of 1-trans- β -3,4dichlorostyrenesulphonylchloride (2.7g) and isonipecotic acid (1.41g) in acetonitrile (15ml) was added 2M sodium hydroxide (11 ml) and stirred at ambient temperature for 1 hour. The reaction mixture was acidified to pH 3 with 2M hydrochloric acid and extracted with ethyl acetate (2x15ml), the ethyl acetate extracts were dried (Na₂SO₄), filtered and evaporated to give 1-trans- β -3,4dichlorostyrenesulphonyl-piperidine-4-carboxylate (2.67g), m/z 364 (M+1).

Example 19

The following compounds were prepared



PIP = piperazinyl

Z = reverse hydroxamate group


R2 = hydrogen

-63-


M+H	B	A	Y	Q	R1	Z
	4-F-Ph	PIP	SO2	CH2	i-Propyl	RH
360	4-F-Ph	PIP	SO2	CH2	Ethyl	RH
386	4-F-Ph	PIP	SO2	CH2	spiro-c-pentyl	RH
450.8	4-F-Ph	PIP	SO2	CH2	4-NMe2-Ph	RH
442	4-F-Ph	PIP	SO2	CH2	4-Cl-Ph	RH
388	4-F-Ph	PIP	SO2	CH2	tert-Butyl	RH
442	4-F-Ph	PIP	SO2	CH2	2-Cl-Ph	RH
484	4-F-Ph	PIP	SO2	CH2	4-Ph-Ph	RH
468	4-F-Ph	PIP	SO2	CH2	2,4-di-OMe-Ph	RH
452.9	4-F-Ph	PIP	SO2	CH2	3-NO2-Ph	RH
475.9	4-F-Ph	PIP	SO2	CH2	4-CF3-Ph	RH
475.9	4-F-Ph	PIP	SO2	CH2	2-CF3-Ph	RH
374	4-F-Ph	PIP	SO2	CH2	Propyl	RH
458	4-F-Ph	PIP	SO2	CH2	1-Naphthyl	RH
387.9	4-F-Ph	PIP	SO2	CH2	3-Furyl	RH
450.9	4-F-Ph	PIP	SO2	CH2	CH2CH2SCH3	RH
388	4-F-Ph	PIP	SO2	CH2	iso-Butyl	RH
491.8	4-F-Ph	PIP	SO2	CH2	4-Br-2-Thiophenyl	RH
485.8	4-F-Ph	PIP	SO2	CH2	3-Br-Ph	RH
458	4-F-Ph	PIP	SO2	CH2	2-Naphthyl	RH
496	4-F-Ph	PIP	SO2	CH2	2-Fluorenyl	RH
466	4-F-Ph	PIP	SO2	CH2	4-CO2Me-Ph	RH
414	4-F-Ph	PIP	SO2	CH2	Cyclohexyl	RH
402	4-F-Ph	PIP	SO2	CH2	2-neopentyl	RH
533.9	4-F-Ph	PIP	SO2	CH2	3-(4-Cl-PhO)-Ph	RH
452	4-F-Ph	PIP	SO2	CH2	PhCH2OCH2	RH
507.9	4-F-Ph	PIP	SO2	CH2	2-(5-4'-Cl-Ph)Furyl	RH
450	4-F-Ph	PIP	SO2	CH2	CH2CH(CH3)Ph	RH
451.9	4-F-Ph	PIP	SO2	CH2	4-Piperonyl	RH
	4-F-Ph	PIP	SO2	CH2	3-(OCH2Ph)Ph	RH
	4-F-Ph	PIP	SO2	CH2	4-(OCH2Ph)Ph	RH
	4-F-Ph	PIP	SO2	CH2	3-CF3-Ph	RH
497.9	4-F-Ph	PIP	SO2	CH2	C6F5	RH

Example 20


We provide NMR data for the following compounds:




(DMSO) 9.6 (1H, s), 8.5 (1H, m), 8.4 and 7.9 (1H, s), 7.7 (1H, m), 7.2 (2H, m), 7.1 (2H, m),
 5 7.0 (2H, m), 4.7 and 4.2 (1H, broad m), 3.4 (1H, m), 3.3 (5H, m), 3.1 (4H, m), 2.7 (2H, m),
 2.1 (2H, m).




(DMSO) 9.8 and 9.5 (1H, broad s), 8.3 and 8.0 (1H, s), 8.1 (1H, d), 7.6 (1H, dd), 7.2 (5H,
 m), 6.9 (1H, d), 4.7 and 4.1 (1H broad m), 3.6 (4H, m), 3.4 (1H, m), 3.3 (1H, m), 3.2 (4H,
 10 m), 2.6 (2H, m), 1.6 (4H, m).




(DMSO) 9.6 (1H, broad S), 8.4 (1H, m), 8.3 and 7.9 (1H, s), 8.1 (1H, d), 7.6 (2H, m), 7.2
 (1H, d), 7.1 (1H, m), 6.9 (1H, d), 4.7 and 4.1 (1H, broad m), 3.6 (4H, m), 3.4 (1H, m), 3.3
 (1H, m), 3.2 (4H, m), 2.7 (2H, m), 2.0 (2H, m).



(DMSO) 9.7 (1H, broad s), 8.5 (1H, m), 8.4 (1H, m), 8.1 and 7.9 (1H, s), 7.6 (1H, m), 7.2 (2H, m), 7.0 (1H, m), 4.6 and 4.1 (1H, broad m), 3.7 (4H, m), 3.4 (1H, m), 3.3 (5H, m), 2.7 (2H, m), 2.0 (2H, m).




- 5 (DMSO) 9.9 (1H, s), 8.4 (2H, m), 8.2 (1H, d), 7.65 (2H, m), 7.3 (1H, m), 7.0 (1H, m), 4.0-4.2 (2H, m), 3.6 (4H, br m), 3.4-3.2 (6H, br m), 2.0 (2H, br m).




(DMSO) 10.0 (1H, s), 8.5 (2H, d), 8.2 (1H, br s), 7.8 (1H, br), 7.6 (1H, m), 7.4 (1H, m), 6.9 (1H, m), 3.6 (4H, br m), 3.2 (6H, br m).


10




10.0 (1H, s), 8.5 (2H, m), 8.4 and 8.0 (1H, s), 7.9 (1H, m), 7.7 (1H, m), 7.3 (1H, m), 7.1 (1H, m), 3.7 (4H, br m), 3.45 (2H, m), 3.3 (4H, br m), 2.75 (3H, m), 2.1 (2H, m).




(DMSO) 10.0 (1H, br s), 8.6 (2H, m), 8.2 (1H, d), 7.2 (1H, m), 6.9 (4H, m), 4.9 and 4.2 (1H, br), 3.4 (6H, m), 3.0 (6H, m), 1.9 (4H, m).



(DMSO) 9.8 (1H, br), 8.7 (2H, m), 8.3 and 7.9 (1H, s), 8.1 (2H, s), 7.6 (1H, m), 7.3 (1H, m),
5 6.9 (1H, m), 4.1 (1H, br m), 3.6 (4H, m), 3.2 (6H, m), 2.8 (2H, m), 1.8 (4H, m).



(CDCl₃) 8.5 (1H, m), 8.1 (2H, s), 8.5 and 8.0 (1H, s), 7.8 (1H, m), 7.4 (1H, m), 7.3 (2H, m),
6.6 (1H, m), 4.8 and 4.2 (1H, br m), 3.6 (4H, m) 3.2 (6H, m), 2.8 (2H, m), 1.8 (4H, m).



10


(DMSO) 8.5 (1H, d), 8.4 and 8.2 (1H, s), 7.7 (1H, m), 7.2 (6H, m), 4.8 and 4.2 (1H, br m),
3.6 (4H, m), 3.2 (6H, m), 2.8 (2H, m), 1.8 (4H, m).

15

20

Example 21

The following compounds were prepared



PIP = piperazinyl

5 Z = reverse hydroxamate group

R2 = hydrogen


Mp Low	Mp High	M+H	B	A	Y	Q	R1	Z
		467	4-C1-Ph	PIP	SO2	CH2	3-PyridylCH(CH3)CH2	RH
55	60	456	4-F-Ph	PIP	SO2	CH2	c hexylC(Me)CH2	RH
125	128	440	4-F-Ph	PIP	SO2	CH2	PhCH2SCH2	RH
130	131	460	4-F-Ph	Piperidinyl	SO2	CH2	2-IndanCH2	RH
64	65	448	4-F-Ph	Piperidinyl	SO2	CH2	(R)-2-PhCH(CH3)CH2	RH
63	64	448	4-F-Ph	Piperidinyl	SO2	CH2	(S)-2-PhCH(CH3)CH2	RH
132	137	484	4-F-Ph	PIP	SO2	CH2	2-C1-PhCH(CH3)CH2	RH
		484	4-F-Ph	PIP	SO2	CH2	4-C1-PhCH(CH3)CH2	RH
		484	4-F-Ph	PIP	SO2	CH2	3-C1-PhCH(CH3)CH2	RH
		469	5-C1-2-Pyridyl	PIP	SO2	CH2	2-PyrazineCH(CH3)CH2	RH
		516	4-F-Ph	PIP	SO2	CH2	4-C1-Ph-S-CH(CH3)CH2	RH
		466	3-C1-Ph	PIP	SO2	CH2	(S)-2-PhCH(CH3)CH2	RH
		467	5-C1-2-Pyridyl	PIP	SO2	CH2	(S)-2-PhCH(CH3)CH2	RH
50	51	450	4-F-Ph	Piperidinyl	SO2	CH2	2-PyrazineCH(CH3)CH2	RH
60	61	454	4-F-Ph	Piperidinyl	SO2	CH2	2-ThiophenylCH(CH3)CH2	RH
82	83	449	4-F-Ph	Piperidinyl	SO2	CH2	4-PyridylCH(CH3)CH2	RH
65	66	407	4-F-Ph	PIP	SO2	CH-Ph		RH
91	100	484	4-F-Ph	PIP	SO2	CH2	PhCH2SOCH2	RH
142	145	484	4-F-Ph	PIP	SO2	CH2	PhCH2SOCH2	RH
		455	5-C1-2-Pyridyl	PIP	SO2	CH2	2-PyrimidinylCH2CH2	RH
		460	5-cyano-2-pyridyl	PIP	SO2	CH2	2-PyrimidinylCH2CH2CH2	RH
		444	5-cyano-2-pyridyl	PIP	SO2	CH2	PhCH2CH2	RH
		464	5-cyano-2-pyridyl	PIP	SO2	CH2	2-ThiophenylCH2CH2CH2	RH
		445	5-cyano-2-pyridyl	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		459	5-cyano-2-pyridyl	PIP	SO2	CH2	2-PyridylCHHH2CH2CH2	RH
		460	5-cyano-2-pyridyl	PIP	SO2	CH2	PhCH2OCH2	RH
		445	5-cyano-2-pyridyl	PIP	SO2	CH2	2-PyridylCH2CH2	RH
		417	5-cyano-2-pyridyl	PIP	SO2	CH2	3-Pyridyl	RH
		498/ 500	5-Br-2-Pyridyl	PIP	SO2	CH2	2-PyridylCH2CH2	RH
		498/ 500	5-Br-2-Pyridyl	PIP	SO2	CH2	3-PyridylCH2CH2	RH
		497/ 499	5-Br-2-Pyridyl	PIP	SO2	CH2	PhCH2CH2	RH
		513/ 515	5-Br-2-Pyridyl	PIP	SO2	CH2	PhCH2OCH2	RH
		470/ 472	5-Br-2-Pyridyl	PIP	SO2	CH2	3-Pyridyl	RH

Mp Low	Mp High	M+H	B	A	Y	Q	R1	Z
		517/ 519	5-Br-2-Pyridyl	PIP	SO2	CH2	2-ThiophenylCH2CH2CH2	RH
		513/ 515	5-Br-2-Pyridyl	PIP	SO2	CH2	2-PyrimidinylCH2CH2CH2	RH
		512/ 514	5-Br-2-Pyridyl	PIP	SO2	CH2	2-PyridylCH2CH2CH2	RH
		436	2-Pyrazinyl	PIP	SO2	CH2	2-PyrimidinylCH2CH2CH2	RH
		439	2-Pyridyl	PIP	SO2	CH2	2-ThiophenylCH2CH2CH2	RH
		440	2-Pyrazinyl	PIP	SO2	CH2	2-ThiophenylCH2CH2CH2	RH
		488.1	5-C1-2-Pyridyl	4-0-Piperid- inyl	SO2	CH2	2-ThiophenylCH2CH2CH2	RH
103	104	484.1	5-C1-2-Pyridyl	4-0-Piperid- inyl	SO2	CH2	2-ThiophenylCH2CH2CH2	RH
		483.3	5-C1-2-Pyridyl	4-0-Piperid- inyl	SO2	CH2	2-PyridylCH2CH2CH2	RH
		508.1	5-C1-2-Pyridyl	4-0-Piperid- inyl	SO2	CH2	3,4-di-C1-Ph	RH
		504/ 506	5-C1-2-Pyridyl	PIP	SO2	CH2	3-Pyridyl-5-bromo	RH
123	125	466.3	6-MeO-4-Pyrimidinyl	PIP	SO2	CH2	PhCH2OCH2	RH
99	101	451.3	6-MeO-4-Pyrimidinyl	PIP	SO2	CH2	2-PyridylCH2CH2	RH
95	99	451.4	6-MeO-4-Pyrimidinyl	PIP	SO2	CH2	3-PyridylCH2CH2	RH
156	158	470.3	6-MeO-4-Pyrimidinyl	PIP	SO2	CH2	2-ThiophenylCH2CH2CH2	RH
122	124	466.3	6-MeO-4-Pyrimidinyl	PIP	SO2	CH2	2-PyrimidinylCH2CH2CH2	RH
		465.3	6-MeO-4-Pyrimidinyl	PIP	SO2	CH2	2-PyridylCH2CH2CH2	RH

All compounds were prepared as in Example 1 except those where ring A is 4-0-piperidinyl which were prepared as in Example 14.


5 Example 22

We provide NMR data for the following compounds listed in Example 21:




M452587 - new compound

NMR (DMSO) 9.9,9.6 (1H broad s); 8.6 (2H m); 8.3 and 7.9 (1H s); 8.1 (1H,dd); 7.3 (1H,m) 6.9 (1H,d); 4.7 and 4.2 (1H broad,m); 3.6 (4H,m); 3.4-3.2 (6H,m); 2.8 (2H,m); 2.1 (2H,m).



(DMSO) 9.9 and 9.6 (1H, broad s), 8.7 (2H, d), 8.3 and 8.0 (1H, s), 8.2 (1H, d), 7.8 (1H, dd), 7.3 (1H, m), 6.9 (1H, d), 5.1 (1H, broad m), 4.7 and 4.1 (1H, broad m), 3.4 (3H, m), 3.1 (3H, m), 2.9 (2H, m), 2.0 (2H, m), 1.7 (6H, m).


Example 23**Preparation of:**

5

To formic acid (4.8ml) at 0°C was added acetic anhydride (1.2ml). After 20 minutes this was added to the hydroxylamine **2** (0.68g) dissolved in THF (11ml) and formic acid (5ml) and the resulting solution stirred overnight at room temperature. The solvent was removed under reduced pressure and the residue dissolved in DCM (100ml), washed with saturated sodium bicarbonate solution (2x100ml), dried (MgSO₄) and evaporated to dryness. The residue was purified by flash column chromatography eluting with dichloromethane / methanol (96:4) to give the product (0.41g) as a gum. NMR CDCl₃ δ 9.7 (br s, 1H)*; 9.2 (br s, 1H)*; 8.4 (s, 1H)*; 8.0 (s, 1H)*; 7.5-7.2 (m, 5H); 7.0-6.8 (m, 4H); 5.7 (m, 1H)*; 5.4 (m, 1H)*; 3.9-3.4 (m, 5H); 3.3 (m, 1H)*; 3.2-2.9 (m, 4H); 2.8 (m, 1H)*. MS for C₂₀H₂₂FN₃O₃ (M+H) calcd 372, found 372.


15

* rotameric signals

Step A

To 1-(4-fluorophenyl)piperazine (1.00g) dissolved in DCM (10ml) was added cinnamoyl chloride (0.85g) in DCM (10ml) followed by triethylamine (1.55ml). The solution was stirred at room temperature overnight.. It was then separated between DCM (150ml) and water (100ml), the organic layer was then washed with water (100ml), dried (MgSO₄) and evaporated to dryness to give a cream solid which was triturated with diethyl ether (10ml) to give **1** (1.20g) as a white solid. NMR CDCl₃ δ 7.7 (d, 1H); 7.5 (m, 2H); 7.4 (m, 3H); 7.0-6.9 (m, 5H); 4.0-3.8 (m, 4H); 3.1 (m, 4H). MS for C₁₉H₁₉FN₂O (M+H) calcd 311, found 311.

10 Step B




To the amide (2.00g) dissolved in THF (40ml) was added hydroxylamine (1ml, 50% aqueous solution). The solution was stirred at room temperature for 48 hours. The solvent was then evaporated under reduced pressure, toluene was added (50ml) and this was also evaporated under reduced pressure. The residue was triturated with dichloromethane / methanol (98:2) and the mother liquor purified by flash column chromatography eluting with dichloromethane / methanol (98:2) to give **2** (0.70g) as a gum. NMR CDCl₃ δ 7.5-7.2 (m, 5H); 7.0-6.9 (m, 2H); 6.9-6.8 (m, 2H); 4.5 (dd, 1H); 3.8-3.7 (m, 2H); 3.6-3.5 (m, 2H); 3.1-2.8 (m, 5H); 2.7 (dd, 1H). MS for C₁₉H₂₂FN₃O₂ (M+H) calcd 344, found 344.

CLAIMS:

What we claim is:-

1. A compound of the formula I

5



wherein ring B is a monocyclic or bicyclic alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl ring comprising up to 12 ring atoms and containing one or more heteroatoms independently chosen from N, O, and S; alternatively ring B may be biphenyl; ring B may optionally be linked to ring A by a C1-4 alkyl or a C1-4 alkoxy chain linking the 2-position of ring B with a carbon atom alpha to X2;

each R3 is independently selected from hydrogen, halogen, NO₂, COOR wherein R is hydrogen or C1-6alkyl, CN, CF₃, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO₂-C1-6 alkyl, C1-6 alkoxy and up to C10 aryloxy, n is 1,2 or 3;

P is -(CH₂)_n- wherein n = 0, 1, 2; or P is an alkene or alkyne chain of up to six carbon atoms; where X2 is C; P may be -Het-, -(CH[R6])_n-Het-, -Het-(CH[R6])_n-or -Het-(CH[R6])_n-Het-, wherein Het is selected from -CO-, -S-, SO-, -SO₂-, -NR6-, or -O- wherein n is 1 or 2; or P may be selected from -CO-N(R6)-, -N(R6)-CO-, -SO₂-N(R6)- and -N(R6)-SO₂-, and R6 is hydrogen, C1-6 alkyl, up to C10 aralkyl or up to C9 heteroalkyl;

Ring A is a 5-7 membered aliphatic ring and may optionally be mono- or di-substituted by optionally substituted C1-6 alkyl or C1-6 alkoxy, each substituent being independently selected from halogen, C1-6 alkyl or an oxo group.

X1 and X2 are independently selected from N and C, where a ring substituent on ring A is an oxo group this is preferably adjacent a ring nitrogen atom;

Y is selected from -SO₂- and -CO-;

Z is -CONHOH, Y is -CO- and Q is selected from -C(R6)(R7)-, -C(R6)(R7)-CH₂-, -N(R6)-, and -N(R6)-CH₂- wherein R6 is as defined above, and solely in relation to Q as here

defined, R6 may also represent up to C10 aryl and up to C9 heteroaryl, and R7 is H, C1-6 alkyl, or together with R6 forms a carbocyclic or heterocyclic spiro 5, 6 or 7 membered ring, the latter containing at least one heteroatom selected from N, O, and S;

Z is -CONHOH, Y is -SO2- and Q is selected from -C(R6)(R7)-, and —C(R6)(R7)-CH2-;

or Z is -N(OH)CHO and Q is selected from -CH(R6)-, -CH(R6)-CH2-, and -N(R6)-CH2-;

R1 is H, C1-6 alkyl, C5-7 cycloalkyl, up to C10aryl, up to C10heteroaryl, up to C12aralkyl, or up to C12heteroarylalkyl, all optionally substituted by up to three groups independently selected from NO2, CF3, halogen, C1-4alkyl, carboxy(C1-4)alkyl, up to C6cycloalkyl, -OR4, -SR4, C1-4alkyl substituted with -OR4, SR4 (and its oxidised analogues), NR4, N-Y-R4, or C1-4alkyl-Y-NR4, with the proviso that where R1 is -OH, -OR4, -SR4, or NR4, or N-Y-R4 then Z is not -N(OH)CHO, or R1 is 2,3,4,5,6-pentafluorophenyl;

R4 is hydrogen, C1-6 alkyl, up to C10 aryl or up to C10 heteroaryl or up to C9 aralkyl, each independently optionally substituted by halogen, NO2, CN, CF3, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO2-C1-6 alkyl or C1-6 alkoxy;

R2 is H, C1-6 alkyl, or together with R1 forms a carbocyclic or heterocyclic spiro 5, 6 or 7 membered ring, the latter containing at least one heteroatom selected from N, O, and S; also the group Q can be linked to either R1 or R2 to form a 5, 6 or 7 membered alkyl or heteroalkyl ring comprising one or more of O, S and N; and wherein any alkyl groups outlined above may be straight chain or branched, or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

2. A compound as claimed in claim 1 and wherein:

ring A is a 5-6 membered aliphatic ring, and may optionally be mono- or di-substituted by optionally substituted C1-6 alkyl or C1-6 alkoxy, each substituent being independently selected from halogen, C1-6 alkyl or an oxo group;

R3 is hydrogen, halogen, NO2, CF3, C1-4 alkyl, and C1-4 alkoxy, n is 1 or 2;

ring B is monocyclic or bicyclic aryl, aralkyl or heteroaryl having up to 10 ring atoms;

P is -(CH2)n- wherein n is 0 or 1, or -O-, or -CO-N(R6)-;

one or both of X2 and X1 = N, or X1 is N, or X2 is C;

R1 is hydrogen, C1-6alkyl, C5-7 cycloalkyl, up to C12aralkyl, up to C11heteroarylalkyl, up to C10 aryl or C10 heteroaryl; all optionally substituted by up to three halogen atoms, or by CF₃;

5 R2 is hydrogen, or together with R1 represent a carbocyclic or heterocyclic spiro 5-or 6 membered ring;

R4 is up to C10 aryl optionally substituted by halogen, NO₂, CN, CF₃, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO₂-C1-6 alkyl or C1-6 alkoxy.

or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

10 3. A compound as claimed in claim 1 wherein:

R3 is hydrogen, halogen, NO₂, CF₃, methyl, ethyl, methoxy or ethoxy;
ring B is a monocyclic aryl, aralkyl or heteroaryl ring having up to 7 ring atoms;
P is a direct bond;

both X₂ and X₁ are N;

15 Y is -SO₂-;

Q is -CH₂-;

R1 is phenyl, 4-trifluoromethylphenyl, phenethyl, phenpropyl, isobutyl, cyclopentyl, benzyloxymethyl, 3,4-dichlorophenyl, 2-pyridyl, 3-pyridyl, 2-pyridylethyl, 3-pyridylethyl, thiophenylpropyl, bromothiophenyl, 2-pyrimidinylethyl, 2-pyrimidinylpropyl, pyridylpropyl
20 or together with R2 is spirocyclohexane or spiro-4-pyran;

R2 is hydrogen

Z is -N(OH)CHO; or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

25 4. A compound as claimed in any one of the previous claims wherein ring A is a piperazinyl ring and ring B is selected from an optionally substituted phenyl, pyridyl or pyrimidine ring; or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

30 5. A compound of the formula I as claimed in claim 1 wherein ring B substituted by R₃(n) is a phenyl, 3-methylphenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, or 3,4-dichlorophenyl ring or is 5-chloro-2-pyridyl; P is a direct bond; ring A is piperidinyl or

piperazinyl; Y is SO₂, Q is -CH₂-, and Z is -N(OH)CHO; or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

6. A compound of the formula I as claimed in claim 1 wherein ring B is a phenyl, 3-methylphenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, or 3,4-dichlorophenyl ring or 5-chloro-2-pyridyl; P is a direct bond; ring A is piperidinyl or piperazinyl, Y is SO₂, Q is -CH₂-, Z is -N(OH)CHO and R₁ is phenyl, phenbutylene, phenisopropylene, 2-pyridylethylene, 2-pyridylisopropylene, 3-pyridylisopropylene, 4-pyridylisopropylene, or 4-chlorophenyloxydimethylmethylene; or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.


7. A compound of the formula I as claimed in claim 1 wherein ring B is phenyl monosubstituted by chlorine or fluorine, P is a direct bond; ring A is piperidinyl, Y is SO₂, Q is -CH₂-, Z is -CONHOH and R₁ is hydrogen, i-butyl, or spiro-tetrahydropyranyl; or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

8. A pharmaceutical composition which comprises a compound of the formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester and a pharmaceutically acceptable carrier.

9. A compound of the formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use in a method of therapeutic treatment of the human or animal body.

10. A method of treating a metalloproteinase mediated disease condition which comprises administering to a warm-blooded animal a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.




11. A process for preparing a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises
a) reacting a compound of the formula (II) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with a compound of the formula (III)



wherein X_1^I represents X or a precursor of X (whether by modification or displacement) or an
 5 activated form of X suitable for reaction with Y_1 ;

Y_1 represents Y, a precursor of Y, or an activated form of Y suitable for reaction with
 X_1^I ; Z^I represents a protected form of Z, a precursor of Z (whether by modification or
 displacement of Z^I) or an activated form of Z;


and where Q is $-(CH_2)(R_6)-$ then by reacting a compound of the formula IX with an
 10 appropriate compound of the formula R_1-CO-R_2 to yield an alkene of the formula X, which
 is then converted to a compound of the formula XI wherein Z^* is a hydroxylamine precursor
 of the group Z, and then converting Z^* to the group Z, all as set out below:



or

b) reacting a compound of the formula (IV) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with a compound of the formula (V).

5



wherein B^I represents a suitable ring function or substituent group for reaction with P^I ;

Z^I is as hereinbefore defined; and

P^I represents a suitably activated form of the linker P for reaction with B^I

or where X2 is N then P1 may be present on ring A rather than ring B
or, as required, the linker P may be formed by appropriate reaction of precursor groups P'' and P''' provided on rings B¹ and A respectively, or vice versa.

- 5 12. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or in
vivo hydrolysable precursor thereof in the preparation of a medicament for use in a disease
condition mediated by one or more metalloproteinase enzymes.
- 10 13. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or in
vivo hydrolysable precursor thereof in the preparation of a medicament for use in the
treatment of arthritis.
- 15 14. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or in
vivo hydrolysable precursor thereof in the preparation of a medicament for use in the
treatment of atherosclerosis.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 99/02801

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D213/42 C07D239/42 C07D295/22 C07D213/74 C07D417/12
C07D401/12 C07D215/12 C07D333/20 C07D241/12 A61K31/44
A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 99 38843 A (DARWIN DISCOVERY LTD) 5 August 1999 (1999-08-05) claims 1,15-25; example 4	1, 10, 12-14
X,P	WO 99 02510 A (BISSOLINO PIERLUIGI ;JABES DANIELA (IT); ALPEGIANI MARCO (IT); PER) 21 January 1999 (1999-01-21) claims 1,8-12; examples	1, 10, 12-14
X	DE 198 02 350 A (HOFFMANN LA ROCHE ;AGOURON PHARMA (US)) 30 July 1998 (1998-07-30) claims 1,79-81; examples	1, 10, 12-14
A	WO 98 16514 A (AMERICAN CYANAMID CO) 23 April 1998 (1998-04-23) claims 1,4-10; example 11	1, 10, 12-14

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

21 December 1999

Date of mailing of the international search report

11/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/ 02801

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 10
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful international Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/02801

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9938843	A	05-08-1999	AU 2291499 A	16-08-1999
WO 9902510	A	21-01-1999	AU 8858398 A	08-02-1999
			EP 0925289 A	30-06-1999
DE 19802350	A	30-07-1998	AU 6614098 A	18-08-1998
			WO 9832748 A	30-07-1998
			EP 0958287 A	24-11-1999
			FR 2758559 A	24-07-1998
			GB 2321641 A	05-08-1998
			HR 980036 A	31-12-1998
			IT MI980091 A	23-07-1998
			NO 993587 A	22-09-1999
			ZA 9800376 A	23-07-1998
WO 9816514	A	23-04-1998	AU 4980697 A	11-05-1998